Drug treatment designed to further diminish the disease toward complete remission following INDUCTION CHEMOTHERAPY. It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
An anthracenedione-derived antineoplastic agent.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Transplantation of an individual's own tissue from one site to another site.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A decrease in the number of NEUTROPHILS found in the blood.
Complex mental function having four distinct phases: (1) memorizing or learning, (2) retention, (3) recall, and (4) recognition. Clinically, it is usually subdivided into immediate, recent, and remote memory.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Disease having a short and relatively severe course.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The persistence to perform a learned behavior (facts or experiences) after an interval has elapsed in which there has been no performance or practice of the behavior.
The affective response to an actual current external danger which subsides with the elimination of the threatening condition.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Tumors or cancer of the human BREAST.
Elements of limited time intervals, contributing to particular results or situations.
Learning that takes place when a conditioned stimulus is paired with an unconditioned stimulus.
A response to a cue that is instrumental in avoiding a noxious experience.
Remembrance of information from 3 or more years previously.
Tumors or cancer of the LUNG.
An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.
A readily reversible suspension of sensorimotor interaction with the environment, usually associated with recumbency and immobility.
Relatively permanent change in behavior that is the result of past experience or practice. The concept includes the acquisition of knowledge.
An organoplatinum compound that possesses antineoplastic activity.
A general term referring to the learning of some particular response.
Almond-shaped group of basal nuclei anterior to the INFERIOR HORN OF THE LATERAL VENTRICLE of the TEMPORAL LOBE. The amygdala is part of the limbic system.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
The principle that items experienced together enter into a connection, so that one tends to reinstate the other.
An induced response to threatening stimuli characterized by the cessation of body movements, except for those that are involved with BREATHING, and the maintenance of an immobile POSTURE.
Antimetabolites that are useful in cancer chemotherapy.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
The process whereby a representation of past experience is elicited.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
Induction of a stress reaction in experimental subjects by means of an electrical shock; applies to either convulsive or non-convulsive states.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Bone lengthening by gradual mechanical distraction. An external fixation device produces the distraction across the bone plate. The technique was originally applied to long bones but in recent years the method has been adapted for use with mandibular implants in maxillofacial surgery.
The combining of administrative and organizational resources of two or more health care facilities.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Organic compounds which contain platinum as an integral part of the molecule.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
The procedure of presenting the conditioned stimulus without REINFORCEMENT to an organism previously conditioned. It refers also to the diminution of a conditioned response resulting from this procedure.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
Learning the correct route through a maze to obtain reinforcement. It is used for human or animal populations. (Thesaurus of Psychological Index Terms, 6th ed)
The relationship between the dose of an administered drug and the response of the organism to the drug.
The return of a sign, symptom, or disease after a remission.
Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
A state in which there is an enhanced potential for sensitivity and an efficient responsiveness to external stimuli.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable.
A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.
Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Treatment designed to help prevent a relapse of a disease following the successful primary treatments (INDUCTION CHEMOTHERAPY and CONSOLIDATION CHEMOTHERAPY) with a long-term low-dose drug therapy.
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
The capacity of the NERVOUS SYSTEM to change its reactivity as the result of successive activations.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
The use of DRUGS to treat a DISEASE or its symptoms. One example is the use of ANTINEOPLASTIC AGENTS to treat CANCER.
The forcible expulsion of the contents of the STOMACH through the MOUTH.
A malignant epithelial tumor with a glandular organization.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
The knowledge or perception that someone or something present has been previously encountered.
Performance of complex motor acts.
Tumors or cancer located in bone tissue or specific BONES.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Antibodies obtained from a single clone of cells grown in mice or rats.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7)
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
A persistent increase in synaptic efficacy, usually induced by appropriate activation of the same synapses. The phenomenological properties of long-term potentiation suggest that it may be a cellular mechanism of learning and memory.
A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Periods of sleep manifested by changes in EEG activity and certain behavioral correlates; includes Stage 1: sleep onset, drowsy sleep; Stage 2: light sleep; Stages 3 and 4: delta sleep, light sleep, deep sleep, telencephalic sleep.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
The observable response an animal makes to any situation.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
An alkylating agent of value against both hematologic malignancies and solid tumors.
Reactions of an individual or groups of individuals with relation to the immediate surrounding area including the animate or inanimate objects within that area.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Antibodies produced by a single clone of cells.
The exposure of the head to roentgen rays or other forms of radioactivity for therapeutic or preventive purposes.
Inorganic compounds which contain platinum as the central atom.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
Drugs used to prevent NAUSEA or VOMITING.
A general term for various neoplastic diseases of the lymphoid tissue.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
A subspecialty of internal medicine concerned with the study of neoplasms.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.
Treatment that combines chemotherapy with radiotherapy.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A series of thoughts, images, or emotions occurring during sleep which are dissociated from the usual stream of consciousness of the waking state.
Tumors or cancer of the LIVER.
Tumors or cancer of the PERITONEUM.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Tumors or cancer of the STOMACH.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.
Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)
X-ray visualization of the chest and organs of the thoracic cavity. It is not restricted to visualization of the lungs.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
A subnormal level of BLOOD PLATELETS.
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
The tendency to explore or investigate a novel environment. It is considered a motivation not clearly distinguishable from curiosity.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)
A cell line derived from cultured tumor cells.
Those federal and state laws, and their enforcement, that protect trade and commerce from unlawful restraints and monopolies or unfair business practices.
The state of being deprived of sleep under experimental conditions, due to life events, or from a wide variety of pathophysiologic causes such as medication effect, chronic illness, psychiatric illness, or sleep disorder.
A stage of sleep characterized by rapid movements of the eye and low voltage fast pattern EEG. It is usually associated with dreaming.
A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.
Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
Type of declarative memory, consisting of personal memory in contrast to general knowledge.
Tumors or cancer of the MEDIASTINUM.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
An anti-inflammatory 9-fluoro-glucocorticoid.
Transplant comprised of an individual's own tissue, transferred from one part of the body to another.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
An outbred strain of rats developed in 1915 by crossing several Wistar Institute white females with a wild gray male. Inbred strains have been derived from this original outbred strain, including Long-Evans cinnamon rats (RATS, INBRED LEC) and Otsuka-Long-Evans-Tokushima Fatty rats (RATS, INBRED OLETF), which are models for Wilson's disease and non-insulin dependent diabetes mellitus, respectively.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Loss of the ability to recall information that had been previously encoded in memory prior to a specified or approximate point in time. This process may be organic or psychogenic in origin. Organic forms may be associated with CRANIOCEREBRAL TRAUMA; CEREBROVASCULAR ACCIDENTS; SEIZURES; DEMENTIA; and a wide variety of other conditions that impair cerebral function. (From Adams et al., Principles of Neurology, 6th ed, pp426-9)
Cyclic hydrocarbons that contain multiple rings and share one or more atoms.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects.
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.
Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
The injection of very small amounts of fluid, often with the aid of a microscope and microsyringes.
Platinum. A heavy, soft, whitish metal, resembling tin, atomic number 78, atomic weight 195.09, symbol Pt. (From Dorland, 28th ed) It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Learning that is manifested in the ability to respond differentially to various stimuli.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Increase in the longest dimension of a bone to correct anatomical deficiencies, congenital, traumatic, or as a result of disease. The lengthening is not restricted to long bones. The usual surgical methods are internal fixation and distraction.
A professional society in the United States whose membership is composed of hospitals.
The effort of two or more parties to secure the business of a third party by offering, usually under fair or equitable rules of business practice, the most favorable terms.
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.

Treatment of acute promyelocytic leukemia for older patients. (1/34)

Acute promyelocytic leukemia (APL) represents a remarkable disease in which leukemogenesis is driven by the PML-RARalpha oncogene and for which targeted treatment with all-trans retinoic acid (ATRA)-based therapy allows substantial chance of cure. APL is seen in a small subset of older patients, with age representing one of the most important prognostic factors for outcome of treatment. Unlike other acute leukemias, the inferior outcomes for APL in older patients relates less to changes in disease biology and more to the increased toxicity of ATRA and the chemotherapy combination regimens used to induce hematologic and molecular responses. Risk-adapted strategies that use less-toxic agents, such as arsenic trioxide, allow treatment of older patients, with greater efficiency and better chances of cure.  (+info)

High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. (2/34)

 (+info)

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. (3/34)

 (+info)

Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission. (4/34)

 (+info)

Curing all patients with acute promyelocytic leukemia: are we there yet? (5/34)

 (+info)

Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. (6/34)

 (+info)

Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. (7/34)

 (+info)

Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. (8/34)

 (+info)

AML is a fast-growing and aggressive form of leukemia that can spread to other parts of the body through the bloodstream. It is most commonly seen in adults over the age of 60, but it can also occur in children.

There are several subtypes of AML, including:

1. Acute promyelocytic leukemia (APL): This is a subtype of AML that is characterized by the presence of a specific genetic abnormality called the PML-RARA fusion gene. It is usually responsive to treatment with chemotherapy and has a good prognosis.
2. Acute myeloid leukemia, not otherwise specified (NOS): This is the most common subtype of AML and does not have any specific genetic abnormalities. It can be more difficult to treat and has a poorer prognosis than other subtypes.
3. Chronic myelomonocytic leukemia (CMML): This is a subtype of AML that is characterized by the presence of too many immature white blood cells called monocytes in the blood and bone marrow. It can progress slowly over time and may require ongoing treatment.
4. Juvenile myeloid leukemia (JMML): This is a rare subtype of AML that occurs in children under the age of 18. It is characterized by the presence of too many immature white blood cells called blasts in the blood and bone marrow.

The symptoms of AML can vary depending on the subtype and the severity of the disease, but they may include:

* Fatigue
* Weakness
* Shortness of breath
* Pale skin
* Easy bruising or bleeding
* Swollen lymph nodes, liver, or spleen
* Bone pain
* Headache
* Confusion or seizures

AML is diagnosed through a combination of physical examination, medical history, and diagnostic tests such as:

1. Complete blood count (CBC): This test measures the number and types of cells in the blood, including red blood cells, white blood cells, and platelets.
2. Bone marrow biopsy: This test involves removing a small sample of bone marrow tissue from the hipbone or breastbone to examine under a microscope for signs of leukemia cells.
3. Genetic testing: This test can help identify specific genetic abnormalities that are associated with AML.
4. Immunophenotyping: This test uses antibodies to identify the surface proteins on leukemia cells, which can help diagnose the subtype of AML.
5. Cytogenetics: This test involves staining the bone marrow cells with dyes to look for specific changes in the chromosomes that are associated with AML.

Treatment for AML typically involves a combination of chemotherapy, targeted therapy, and in some cases, bone marrow transplantation. The specific treatment plan will depend on the subtype of AML, the patient's age and overall health, and other factors. Some common treatments for AML include:

1. Chemotherapy: This involves using drugs to kill cancer cells. The most commonly used chemotherapy drugs for AML are cytarabine (Ara-C) and anthracyclines such as daunorubicin (DaunoXome) and idarubicin (Idamycin).
2. Targeted therapy: This involves using drugs that specifically target the genetic abnormalities that are causing the cancer. Examples of targeted therapies used for AML include midostaurin (Rydapt) and gilteritinib (Xospata).
3. Bone marrow transplantation: This involves replacing the diseased bone marrow with healthy bone marrow from a donor. This is typically done after high-dose chemotherapy to destroy the cancer cells.
4. Supportive care: This includes treatments to manage symptoms and side effects of the disease and its treatment, such as anemia, infection, and bleeding. Examples of supportive care for AML include blood transfusions, antibiotics, and platelet transfusions.
5. Clinical trials: These are research studies that involve testing new treatments for AML. Participating in a clinical trial may give patients access to innovative therapies that are not yet widely available.

It's important to note that the treatment plan for AML is highly individualized, and the specific treatments used will depend on the patient's age, overall health, and other factors. Patients should work closely with their healthcare team to determine the best course of treatment for their specific needs.

Myeloid leukemia can be classified into several subtypes based on the type of cell involved and the degree of maturity of the abnormal cells. The most common types of myeloid leukemia include:

1. Acute Myeloid Leukemia (AML): This is the most aggressive form of myeloid leukemia, characterized by a rapid progression of immature cells that do not mature or differentiate into normal cells. AML can be further divided into several subtypes based on the presence of certain genetic mutations or chromosomal abnormalities.
2. Chronic Myeloid Leukemia (CML): This is a slower-growing form of myeloid leukemia, characterized by the presence of a genetic abnormality known as the Philadelphia chromosome. CML is typically treated with targeted therapies or bone marrow transplantation.
3. Myelodysplastic Syndrome (MDS): This is a group of disorders characterized by the impaired development of immature blood cells in the bone marrow. MDS can progress to AML if left untreated.
4. Chronic Myelomonocytic Leukemia (CMML): This is a rare form of myeloid leukemia that is characterized by the accumulation of immature monocytes in the blood and bone marrow. CMML can be treated with chemotherapy or bone marrow transplantation.

The symptoms of myeloid leukemia can vary depending on the subtype and severity of the disease. Common symptoms include fatigue, weakness, fever, night sweats, and weight loss. Diagnosis is typically made through a combination of physical examination, blood tests, and bone marrow biopsy. Treatment options for myeloid leukemia can include chemotherapy, targeted therapies, bone marrow transplantation, and supportive care to manage symptoms and prevent complications. The prognosis for myeloid leukemia varies depending on the subtype of the disease and the patient's overall health. With current treatments, many patients with myeloid leukemia can achieve long-term remission or even be cured.

Pre-B ALL is characterized by the abnormal growth of immature white blood cells called B lymphocytes. These cells are produced in the bone marrow and are normally present in the blood. In Pre-B ALL, the abnormal B cells accumulate in the bone marrow, blood, and other organs, crowding out normal cells and causing a variety of symptoms.

The symptoms of Pre-B ALL can vary depending on the individual patient, but may include:

* Fatigue
* Easy bruising or bleeding
* Frequent infections
* Swollen lymph nodes
* Enlarged liver or spleen
* Bone pain
* Headaches
* Confusion or seizures (in severe cases)

Pre-B ALL is most commonly diagnosed in children, but it can also occur in adults. Treatment typically involves a combination of chemotherapy and sometimes bone marrow transplantation. The prognosis for Pre-B ALL is generally good, especially in children, with a high survival rate if treated promptly and effectively. However, the cancer can be more difficult to treat in adults, and the prognosis may be less favorable.

Overall, Pre-B ALL is a rare and aggressive form of leukemia that requires prompt and specialized treatment to improve outcomes for patients.

PALL is a rare form of leukemia, accounting for only about 5-10% of all cases of acute leukemia. It is most commonly seen in adults between the ages of 40 and 60, although it can occur at any age.

The symptoms of PALL are similar to those of other types of leukemia and may include fatigue, fever, night sweats, weight loss, and an enlarged spleen. The diagnosis of PALL is typically made through a combination of physical examination, medical history, and laboratory tests, including a bone marrow biopsy.

Treatment for PALL usually involves chemotherapy, which can be effective in achieving a complete remission in many cases. In some instances, bone marrow transplantation may also be considered as a form of treatment. The prognosis for PALL is generally poor, with a five-year survival rate of about 20-30%. However, with prompt and appropriate treatment, many people with PALL can achieve long-term remission and a good quality of life.

Symptoms of neutropenia may include recurring infections, fever, fatigue, weight loss, and swollen lymph nodes. The diagnosis is typically made through a blood test that measures the number of neutrophils in the blood.

Treatment options for neutropenia depend on the underlying cause but may include antibiotics, supportive care to manage symptoms, and in severe cases, bone marrow transplantation or granulocyte-colony stimulating factor (G-CSF) therapy to increase neutrophil production.

Examples of acute diseases include:

1. Common cold and flu
2. Pneumonia and bronchitis
3. Appendicitis and other abdominal emergencies
4. Heart attacks and strokes
5. Asthma attacks and allergic reactions
6. Skin infections and cellulitis
7. Urinary tract infections
8. Sinusitis and meningitis
9. Gastroenteritis and food poisoning
10. Sprains, strains, and fractures.

Acute diseases can be treated effectively with antibiotics, medications, or other therapies. However, if left untreated, they can lead to chronic conditions or complications that may require long-term care. Therefore, it is important to seek medical attention promptly if symptoms persist or worsen over time.

There are different types of Breast Neoplasms such as:

1. Fibroadenomas: These are benign tumors that are made up of glandular and fibrous tissues. They are usually small and round, with a smooth surface, and can be moved easily under the skin.

2. Cysts: These are fluid-filled sacs that can develop in both breast tissue and milk ducts. They are usually benign and can disappear on their own or be drained surgically.

3. Ductal Carcinoma In Situ (DCIS): This is a precancerous condition where abnormal cells grow inside the milk ducts. If left untreated, it can progress to invasive breast cancer.

4. Invasive Ductal Carcinoma (IDC): This is the most common type of breast cancer and starts in the milk ducts but grows out of them and invades surrounding tissue.

5. Invasive Lobular Carcinoma (ILC): It originates in the milk-producing glands (lobules) and grows out of them, invading nearby tissue.

Breast Neoplasms can cause various symptoms such as a lump or thickening in the breast or underarm area, skin changes like redness or dimpling, change in size or shape of one or both breasts, discharge from the nipple, and changes in the texture or color of the skin.

Treatment options for Breast Neoplasms may include surgery such as lumpectomy, mastectomy, or breast-conserving surgery, radiation therapy which uses high-energy beams to kill cancer cells, chemotherapy using drugs to kill cancer cells, targeted therapy which uses drugs or other substances to identify and attack cancer cells while minimizing harm to normal cells, hormone therapy, immunotherapy, and clinical trials.

It is important to note that not all Breast Neoplasms are cancerous; some are benign (non-cancerous) tumors that do not spread or grow.

There are several types of lung neoplasms, including:

1. Adenocarcinoma: This is the most common type of lung cancer, accounting for approximately 40% of all lung cancers. It is a malignant tumor that originates in the glands of the respiratory tract and can be found in any part of the lung.
2. Squamous cell carcinoma: This type of lung cancer accounts for approximately 25% of all lung cancers and is more common in men than women. It is a malignant tumor that originates in the squamous cells lining the airways of the lungs.
3. Small cell lung cancer (SCLC): This is a highly aggressive form of lung cancer that accounts for approximately 15% of all lung cancers. It is often found in the central parts of the lungs and can spread quickly to other parts of the body.
4. Large cell carcinoma: This is a rare type of lung cancer that accounts for only about 5% of all lung cancers. It is a malignant tumor that originates in the large cells of the respiratory tract and can be found in any part of the lung.
5. Bronchioalveolar carcinoma (BAC): This is a rare type of lung cancer that originates in the cells lining the airways and alveoli of the lungs. It is more common in women than men and tends to affect older individuals.
6. Lymphangioleiomyomatosis (LAM): This is a rare, progressive, and often fatal lung disease that primarily affects women of childbearing age. It is characterized by the growth of smooth muscle-like cells in the lungs and can lead to cysts, lung collapse, and respiratory failure.
7. Hamartoma: This is a benign tumor that originates in the tissue of the lungs and is usually found in children. It is characterized by an overgrowth of normal lung tissue and can be treated with surgery.
8. Secondary lung cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
9. Metastatic cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
10. Mesothelioma: This is a rare and aggressive form of cancer that originates in the lining of the lungs or abdomen. It is caused by asbestos exposure and can be treated with surgery, chemotherapy, and radiation therapy.

Lung diseases can also be classified based on their cause, such as:

1. Infectious diseases: These are caused by bacteria, viruses, or other microorganisms and can include pneumonia, tuberculosis, and bronchitis.
2. Autoimmune diseases: These are caused by an overactive immune system and can include conditions such as sarcoidosis and idiopathic pulmonary fibrosis.
3. Genetic diseases: These are caused by inherited mutations in genes that affect the lungs and can include cystic fibrosis and primary ciliary dyskinesia.
4. Environmental diseases: These are caused by exposure to harmful substances such as tobacco smoke, air pollution, and asbestos.
5. Radiological diseases: These are caused by exposure to ionizing radiation and can include conditions such as radiographic breast cancer and lung cancer.
6. Vascular diseases: These are caused by problems with the blood vessels in the lungs and can include conditions such as pulmonary embolism and pulmonary hypertension.
7. Tumors: These can be benign or malignant and can include conditions such as lung metastases and lung cancer.
8. Trauma: This can include injuries to the chest or lungs caused by accidents or other forms of trauma.
9. Congenital diseases: These are present at birth and can include conditions such as bronchopulmonary foregut malformations and congenital cystic adenomatoid malformation.

Each type of lung disease has its own set of symptoms, diagnosis, and treatment options. It is important to seek medical attention if you experience any persistent or severe respiratory symptoms, as early diagnosis and treatment can improve outcomes and quality of life.

This definition of 'Neoplasm Recurrence, Local' is from the Healthcare Professionals edition of the Merriam-Webster Medical Dictionary, copyright © 2007 by Merriam-Webster, Inc.

There are several subtypes of NHL, including:

1. B-cell lymphomas (such as diffuse large B-cell lymphoma and follicular lymphoma)
2. T-cell lymphomas (such as peripheral T-cell lymphoma and mycosis fungoides)
3. Natural killer cell lymphomas (such as nasal NK/T-cell lymphoma)
4. Histiocyte-rich B-cell lymphoma
5. Primary mediastinal B-cell lymphoma
6. Mantle cell lymphoma
7. Waldenström macroglobulinemia
8. Lymphoplasmacytoid lymphoma
9. Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) related lymphoma

These subtypes can be further divided into other categories based on the specific characteristics of the cancer cells.

Symptoms of NHL can vary depending on the location and size of the tumor, but may include:

* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching
* Abdominal pain
* Swollen spleen

Treatment for NHL typically involves a combination of chemotherapy, radiation therapy, and in some cases, targeted therapy or immunotherapy. The specific treatment plan will depend on the subtype of NHL, the stage of the cancer, and other individual factors.

Overall, NHL is a complex and diverse group of cancers that require specialized care from a team of medical professionals, including hematologists, oncologists, radiation therapists, and other support staff. With advances in technology and treatment options, many people with NHL can achieve long-term remission or a cure.

Neoplasm refers to an abnormal growth of cells that can be benign (non-cancerous) or malignant (cancerous). Neoplasms can occur in any part of the body and can affect various organs and tissues. The term "neoplasm" is often used interchangeably with "tumor," but while all tumors are neoplasms, not all neoplasms are tumors.

Types of Neoplasms

There are many different types of neoplasms, including:

1. Carcinomas: These are malignant tumors that arise in the epithelial cells lining organs and glands. Examples include breast cancer, lung cancer, and colon cancer.
2. Sarcomas: These are malignant tumors that arise in connective tissue, such as bone, cartilage, and fat. Examples include osteosarcoma (bone cancer) and soft tissue sarcoma.
3. Lymphomas: These are cancers of the immune system, specifically affecting the lymph nodes and other lymphoid tissues. Examples include Hodgkin lymphoma and non-Hodgkin lymphoma.
4. Leukemias: These are cancers of the blood and bone marrow that affect the white blood cells. Examples include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
5. Melanomas: These are malignant tumors that arise in the pigment-producing cells called melanocytes. Examples include skin melanoma and eye melanoma.

Causes and Risk Factors of Neoplasms

The exact causes of neoplasms are not fully understood, but there are several known risk factors that can increase the likelihood of developing a neoplasm. These include:

1. Genetic predisposition: Some people may be born with genetic mutations that increase their risk of developing certain types of neoplasms.
2. Environmental factors: Exposure to certain environmental toxins, such as radiation and certain chemicals, can increase the risk of developing a neoplasm.
3. Infection: Some neoplasms are caused by viruses or bacteria. For example, human papillomavirus (HPV) is a common cause of cervical cancer.
4. Lifestyle factors: Factors such as smoking, excessive alcohol consumption, and a poor diet can increase the risk of developing certain types of neoplasms.
5. Family history: A person's risk of developing a neoplasm may be higher if they have a family history of the condition.

Signs and Symptoms of Neoplasms

The signs and symptoms of neoplasms can vary depending on the type of cancer and where it is located in the body. Some common signs and symptoms include:

1. Unusual lumps or swelling
2. Pain
3. Fatigue
4. Weight loss
5. Change in bowel or bladder habits
6. Unexplained bleeding
7. Coughing up blood
8. Hoarseness or a persistent cough
9. Changes in appetite or digestion
10. Skin changes, such as a new mole or a change in the size or color of an existing mole.

Diagnosis and Treatment of Neoplasms

The diagnosis of a neoplasm usually involves a combination of physical examination, imaging tests (such as X-rays, CT scans, or MRI scans), and biopsy. A biopsy involves removing a small sample of tissue from the suspected tumor and examining it under a microscope for cancer cells.

The treatment of neoplasms depends on the type, size, location, and stage of the cancer, as well as the patient's overall health. Some common treatments include:

1. Surgery: Removing the tumor and surrounding tissue can be an effective way to treat many types of cancer.
2. Chemotherapy: Using drugs to kill cancer cells can be effective for some types of cancer, especially if the cancer has spread to other parts of the body.
3. Radiation therapy: Using high-energy radiation to kill cancer cells can be effective for some types of cancer, especially if the cancer is located in a specific area of the body.
4. Immunotherapy: Boosting the body's immune system to fight cancer can be an effective treatment for some types of cancer.
5. Targeted therapy: Using drugs or other substances to target specific molecules on cancer cells can be an effective treatment for some types of cancer.

Prevention of Neoplasms

While it is not always possible to prevent neoplasms, there are several steps that can reduce the risk of developing cancer. These include:

1. Avoiding exposure to known carcinogens (such as tobacco smoke and radiation)
2. Maintaining a healthy diet and lifestyle
3. Getting regular exercise
4. Not smoking or using tobacco products
5. Limiting alcohol consumption
6. Getting vaccinated against certain viruses that are associated with cancer (such as human papillomavirus, or HPV)
7. Participating in screening programs for early detection of cancer (such as mammograms for breast cancer and colonoscopies for colon cancer)
8. Avoiding excessive exposure to sunlight and using protective measures such as sunscreen and hats to prevent skin cancer.

It's important to note that not all cancers can be prevented, and some may be caused by factors that are not yet understood or cannot be controlled. However, by taking these steps, individuals can reduce their risk of developing cancer and improve their overall health and well-being.

A residual neoplasm is a remaining portion of a tumor that may persist after primary treatment. This can occur when the treatment does not completely remove all of the cancer cells or if some cancer cells are resistant to the treatment. Residual neoplasms can be benign (non-cancerous) or malignant (cancerous).

It is important to note that a residual neoplasm does not necessarily mean that the cancer has come back. In some cases, a residual neoplasm may be present from the start and may not grow or change over time.

Residual neoplasms can be managed with additional treatment, such as surgery, chemotherapy, or radiation therapy. The choice of treatment depends on the type of cancer, the size and location of the residual neoplasm, and other factors.

It is important to follow up with your healthcare provider regularly to monitor the residual neoplasm and ensure that it is not growing or causing any symptoms.

Benign ovarian neoplasms include:

1. Serous cystadenoma: A fluid-filled sac that develops on the surface of the ovary.
2. Mucinous cystadenoma: A tumor that is filled with mucin, a type of protein.
3. Endometrioid tumors: Tumors that are similar to endometrial tissue (the lining of the uterus).
4. Theca cell tumors: Tumors that develop in the supportive tissue of the ovary called theca cells.

Malignant ovarian neoplasms include:

1. Epithelial ovarian cancer (EOC): The most common type of ovarian cancer, which arises from the surface epithelium of the ovary.
2. Germ cell tumors: Tumors that develop from germ cells, which are the cells that give rise to eggs.
3. Stromal sarcomas: Tumors that develop in the supportive tissue of the ovary.

Ovarian neoplasms can cause symptoms such as pelvic pain, abnormal bleeding, and abdominal swelling. They can also be detected through pelvic examination, imaging tests such as ultrasound and CT scan, and biopsy. Treatment options for ovarian neoplasms depend on the type, stage, and location of the tumor, and may include surgery, chemotherapy, and radiation therapy.

Adenocarcinoma is the most common subtype of NSCLC and is characterized by malignant cells that have glandular or secretory properties. Squamous cell carcinoma is less common and is characterized by malignant cells that resemble squamous epithelium. Large cell carcinoma is a rare subtype and is characterized by large, poorly differentiated cells.

The main risk factor for developing NSCLC is tobacco smoking, which is responsible for approximately 80-90% of all cases. Other risk factors include exposure to secondhand smoke, radon gas, asbestos, and certain chemicals in the workplace or environment.

Symptoms of NSCLC can include coughing, chest pain, shortness of breath, and fatigue. The diagnosis is typically made through a combination of imaging studies such as CT scans, PET scans, and biopsy. Treatment options for NSCLC can include surgery, chemotherapy, radiation therapy, or a combination of these. The prognosis for NSCLC depends on several factors, including the stage of the cancer, the patient's overall health, and the effectiveness of treatment.

Overall, NSCLC is a common and aggressive form of lung cancer that can be treated with a variety of therapies. Early detection and treatment are critical for improving outcomes in patients with this diagnosis.

Recurrence can also refer to the re-emergence of symptoms in a previously treated condition, such as a chronic pain condition that returns after a period of remission.

In medical research, recurrence is often studied to understand the underlying causes of disease progression and to develop new treatments and interventions to prevent or delay its return.

Hodgkin Disease can spread to other parts of the body through the lymphatic system, and it can affect people of all ages, although it is most common in young adults and teenagers. The symptoms of Hodgkin Disease can vary depending on the stage of the disease, but they may include swollen lymph nodes, fever, night sweats, fatigue, weight loss, and itching.

There are several types of Hodgkin Disease, including:

* Classical Hodgkin Disease: This is the most common type of Hodgkin Disease and is characterized by the presence of Reed-Sternberg cells.
* Nodular Lymphocytic predominant Hodgkin Disease: This type of Hodgkin Disease is characterized by the presence of nodules in the lymph nodes.
* Mixed Cellularity Hodgkin Disease: This type of Hodgkin Disease is characterized by a mixture of Reed-Sternberg cells and other immune cells.

Hodgkin Disease is usually diagnosed with a biopsy, which involves removing a sample of tissue from the affected lymph node or other area and examining it under a microscope for cancer cells. Treatment for Hodgkin Disease typically involves chemotherapy, radiation therapy, or a combination of both. In some cases, bone marrow or stem cell transplantation may be necessary.

The prognosis for Hodgkin Disease is generally good, especially if the disease is detected and treated early. According to the American Cancer Society, the 5-year survival rate for people with Hodgkin Disease is about 85%. However, the disease can sometimes recur after treatment, and the long-term effects of radiation therapy and chemotherapy can include infertility, heart problems, and an increased risk of secondary cancers.

Hodgkin Disease is a rare form of cancer that affects the immune system. It is most commonly diagnosed in young adults and is usually treatable with chemotherapy or radiation therapy. However, the disease can sometimes recur after treatment, and the long-term effects of treatment can include infertility, heart problems, and an increased risk of secondary cancers.

Neoplastic metastasis can occur in any type of cancer but are more common in solid tumors such as carcinomas (breast, lung, colon). It is important for cancer diagnosis and prognosis because metastasis indicates that the cancer has spread beyond its original site and may be more difficult to treat.

Metastases can appear at any distant location but commonly found sites include the liver, lungs, bones, brain, and lymph nodes. The presence of metastases indicates a higher stage of cancer which is associated with lower survival rates compared to localized cancer.

Testicular neoplasms refer to abnormal growths or tumors that develop in the testicles, which are located inside the scrotum. These tumors can be benign (non-cancerous) or malignant (cancerous). Testicular neoplasms can affect men of all ages, but they are more common in younger men between the ages of 20 and 35.

Types of Testicular Neoplasms:

There are several types of testicular neoplasms, including:

1. Seminoma: This is a type of malignant tumor that develops from immature cells in the testicles. It is the most common type of testicular cancer and tends to grow slowly.
2. Non-seminomatous germ cell tumors (NSGCT): These are malignant tumors that develop from immature cells in the testicles, but they do not have the characteristic features of seminoma. They can be either heterologous (containing different types of cells) or homologous (containing only one type of cell).
3. Leydig cell tumors: These are rare malignant tumors that develop in the Leydig cells, which produce testosterone in the testicles.
4. Sertoli cell tumors: These are rare malignant tumors that develop in the Sertoli cells, which support the development of sperm in the testicles.
5. Testicular metastasectomy: This is a procedure to remove cancer that has spread to the testicles from another part of the body, such as the lungs or liver.

Causes and Risk Factors:

The exact cause of testicular neoplasms is not known, but there are several risk factors that have been linked to an increased risk of developing these tumors. These include:

1. Undescended testicles (cryptorchidism): This condition occurs when the testicles do not descend into the scrotum during fetal development.
2. Family history: Men with a family history of testicular cancer are at an increased risk of developing these tumors.
3. Previous radiation exposure: Men who have had radiation therapy to the pelvic area, especially during childhood or adolescence, have an increased risk of developing testicular neoplasms.
4. Genetic mutations: Certain genetic mutations, such as those associated with familial testicular cancer syndrome, can increase the risk of developing testicular neoplasms.
5. Infertility: Men who are infertile may have an increased risk of developing testicular cancer.

Symptoms:

The symptoms of testicular neoplasms can vary depending on the type and location of the tumor. Some common symptoms include:

1. A lump or swelling in the testicle
2. Pain or discomfort in the testicle or scrotum
3. Enlargement of the testicle
4. Abnormality in the size or shape of the testicle
5. Pain during ejaculation
6. Difficulty urinating or painful urination
7. Breast tenderness or enlargement
8. Lower back pain
9. Fatigue
10. Weight loss

Diagnosis:

The diagnosis of testicular neoplasms typically involves a combination of physical examination, imaging studies, and biopsy.

1. Physical examination: A doctor will perform a thorough physical examination of the testicles, including checking for any abnormalities in size, shape, or tenderness.
2. Imaging studies: Imaging studies such as ultrasound, CT scans, or MRI may be used to help identify the location and extent of the tumor.
3. Biopsy: A biopsy is a procedure in which a small sample of tissue is removed from the testicle and examined under a microscope for cancer cells.
4. Blood tests: Blood tests may be performed to check for elevated levels of certain substances that can indicate the presence of cancer.

Treatment:

The treatment of testicular neoplasms depends on the type, location, and stage of the tumor. Some common treatments include:

1. Surgery: Surgery is often the first line of treatment for testicular neoplasms. The goal of surgery is to remove the tumor and any affected tissue.
2. Chemotherapy: Chemotherapy may be used in combination with surgery or radiation therapy to treat more advanced cancers.
3. Radiation therapy: Radiation therapy uses high-energy beams to kill cancer cells. It may be used in combination with surgery or chemotherapy.
4. Surveillance: Surveillance is a close monitoring of the patient's condition, including regular check-ups and imaging studies, to detect any recurrences of the tumor.

Prognosis:

The prognosis for testicular neoplasms depends on the type, location, and stage of the tumor. In general, the earlier the cancer is detected and treated, the better the prognosis. Some common types of testicular neoplasms have a good prognosis, while others are more aggressive and may have a poorer prognosis if not treated promptly.

Complications:

Some complications of testicular neoplasms include:

1. Recurrence: The cancer can recur in the testicle or spread to other parts of the body.
2. Spread to other parts of the body: Testicular cancer can spread to other parts of the body, such as the lungs, liver, or brain.
3. Infertility: Some treatments for testicular cancer, such as chemotherapy and radiation therapy, can cause infertility.
4. Hormone imbalance: Some types of testicular cancer can disrupt hormone levels, leading to symptoms such as breast enlargement or low sex drive.
5. Chronic pain: Some men may experience chronic pain in the testicle or scrotum after treatment for testicular cancer.

Lifestyle changes:

There are no specific lifestyle changes that can prevent testicular neoplasms, but some general healthy habits can help reduce the risk of developing these types of tumors. These include:

1. Maintaining a healthy weight and diet
2. Getting regular exercise
3. Limiting alcohol consumption
4. Avoiding smoking and recreational drugs
5. Protecting the testicles from injury or trauma

Screening:

There is no standard screening test for testicular neoplasms, but men can perform a self-exam to check for any abnormalities in their testicles. This involves gently feeling the testicles for any lumps or unusual texture. Men with a family history of testicular cancer should talk to their doctor about whether they should start screening earlier and more frequently.

Treatment:

The treatment of testicular neoplasms depends on the type, stage, and location of the tumor. Some common treatments include:

1. Surgery: This involves removing the affected testicle or tumor.
2. Chemotherapy: This involves using drugs to kill cancer cells.
3. Radiation therapy: This involves using high-energy rays to kill cancer cells.
4. Hormone therapy: This involves taking medications to alter hormone levels and slow the growth of cancer cells.
5. Clinical trials: These involve testing new treatments or combination of treatments for testicular neoplasms.

Prognosis:

The prognosis for testicular neoplasms varies depending on the type, stage, and location of the tumor. In general, the earlier the cancer is detected and treated, the better the prognosis. For example, seminoma has a high cure rate with current treatments, while non-seminomatous germ cell tumors have a lower cure rate but can still be effectively treated. Lymphoma and metastatic testicular cancer have a poorer prognosis and require aggressive treatment.

Lifestyle Changes:

There are no specific lifestyle changes that can prevent testicular neoplasms, but some risk factors such as smoking and alcohol consumption can be reduced to lower the risk of developing these tumors. Maintaining a healthy diet, regular exercise, and avoiding exposure to harmful chemicals can also help improve overall health and well-being.

Complications:

Testicular neoplasms can have several complications, including:

1. Infertility: Some treatments for testicular cancer, such as surgery or chemotherapy, can cause infertility.
2. Pain: Testicular cancer can cause pain in the scrotum, groin, or abdomen.
3. Swelling: Testicular cancer can cause swelling in the scrotum or groin.
4. Hormonal imbalance: Some testicular tumors can produce hormones that can cause an imbalance in the body's hormone levels.
5. Recurrence: Testicular cancer can recur after treatment, and regular follow-up is necessary to detect any signs of recurrence early.
6. Late effects of treatment: Some treatments for testicular cancer, such as chemotherapy, can have long-term effects on the body, including infertility, heart problems, and bone marrow suppression.
7. Metastasis: Testicular cancer can spread to other parts of the body, including the lungs, liver, and bones, which can be life-threatening.

Prevention:

There is no specific prevention for testicular neoplasms, but some risk factors such as undescended testes, family history, and exposure to certain chemicals can be reduced to lower the risk of developing these tumors. Regular self-examination and early detection are crucial in improving outcomes for patients with testicular cancer.

Conclusion:

Testicular neoplasms are a rare but potentially life-threatening condition that requires prompt and accurate diagnosis and treatment. Early detection through regular self-examination and follow-up can improve outcomes, while awareness of risk factors and symptoms is essential in reducing the burden of this disease. A multidisciplinary approach involving urologists, radiologists, pathologists, and oncologists is necessary for optimal management of patients with testicular neoplasms.

Vomiting can be caused by a variety of factors, such as:

1. Infection: Viral or bacterial infections can inflame the stomach and intestines, leading to vomiting.
2. Food poisoning: Consuming contaminated or spoiled food can cause vomiting.
3. Motion sickness: Traveling by car, boat, plane, or other modes of transportation can cause motion sickness, which leads to vomiting.
4. Alcohol or drug overconsumption: Drinking too much alcohol or taking certain medications can irritate the stomach and cause vomiting.
5. Pregnancy: Hormonal changes during pregnancy can cause nausea and vomiting, especially during the first trimester.
6. Other conditions: Vomiting can also be a symptom of other medical conditions such as appendicitis, pancreatitis, and migraines.

When someone is vomiting, they may experience:

1. Nausea: A feeling of queasiness or sickness in the stomach.
2. Abdominal pain: Crampy or sharp pain in the abdomen.
3. Diarrhea: Loose, watery stools.
4. Dehydration: Loss of fluids and electrolytes.
5. Headache: A throbbing headache can occur due to dehydration.
6. Fatigue: Weakness and exhaustion.

Treatment for vomiting depends on the underlying cause, but may include:

1. Fluid replacement: Drinking fluids to replenish lost electrolytes and prevent dehydration.
2. Medications: Anti-inflammatory drugs or antibiotics may be prescribed to treat infections or other conditions causing vomiting.
3. Rest: Resting the body and avoiding strenuous activities.
4. Dietary changes: Avoiding certain foods or substances that trigger vomiting.
5. Hospitalization: In severe cases of vomiting, hospitalization may be necessary to monitor and treat underlying conditions.

It is important to seek medical attention if the following symptoms occur with vomiting:

1. Severe abdominal pain.
2. Fever above 101.5°F (38.6°C).
3. Blood in vomit or stools.
4. Signs of dehydration, such as excessive thirst, dark urine, or dizziness.
5. Vomiting that lasts for more than 2 days.
6. Frequent vomiting with no relief.

Adenocarcinoma is a term used to describe a variety of different types of cancer that arise in glandular tissue, including:

1. Colorectal adenocarcinoma (cancer of the colon or rectum)
2. Breast adenocarcinoma (cancer of the breast)
3. Prostate adenocarcinoma (cancer of the prostate gland)
4. Pancreatic adenocarcinoma (cancer of the pancreas)
5. Lung adenocarcinoma (cancer of the lung)
6. Thyroid adenocarcinoma (cancer of the thyroid gland)
7. Skin adenocarcinoma (cancer of the skin)

The symptoms of adenocarcinoma depend on the location of the cancer and can include:

1. Blood in the stool or urine
2. Abdominal pain or discomfort
3. Changes in bowel habits
4. Unusual vaginal bleeding (in the case of endometrial adenocarcinoma)
5. A lump or thickening in the breast or elsewhere
6. Weight loss
7. Fatigue
8. Coughing up blood (in the case of lung adenocarcinoma)

The diagnosis of adenocarcinoma is typically made through a combination of imaging tests, such as CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a sample of tissue from the affected area and examining it under a microscope for cancer cells.

Treatment options for adenocarcinoma depend on the location of the cancer and can include:

1. Surgery to remove the tumor
2. Chemotherapy, which involves using drugs to kill cancer cells
3. Radiation therapy, which involves using high-energy X-rays or other particles to kill cancer cells
4. Targeted therapy, which involves using drugs that target specific molecules on cancer cells to kill them
5. Immunotherapy, which involves using drugs that stimulate the immune system to fight cancer cells.

The prognosis for adenocarcinoma is generally good if the cancer is detected and treated early, but it can be more challenging to treat if the cancer has spread to other parts of the body.

In medical terminology, nausea is sometimes used interchangeably with the term "dyspepsia," which refers to a general feeling of discomfort or unease in the stomach, often accompanied by symptoms such as bloating, belching, or heartburn. However, while nausea and dyspepsia can be related, they are not always the same thing, and it's important to understand the specific underlying cause of any gastrointestinal symptoms in order to provide appropriate treatment.

Some common causes of nausea include:

* Gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and gastritis
* Motion sickness or seasickness
* Medication side effects, including chemotherapy drugs, antibiotics, and painkillers
* Pregnancy and morning sickness
* Food poisoning or other infections
* Migraines and other headaches
* Anxiety and stress

Treatment for nausea will depend on the underlying cause, but may include medications such as antihistamines, anticholinergics, or anti-nausea drugs, as well as non-pharmacological interventions such as ginger, acupressure, or relaxation techniques. In severe cases, hospitalization may be necessary to manage symptoms and prevent dehydration or other complications.

Some common types of bone neoplasms include:

* Osteochondromas: These are benign tumors that grow on the surface of a bone.
* Giant cell tumors: These are benign tumors that can occur in any bone of the body.
* Chondromyxoid fibromas: These are rare, benign tumors that develop in the cartilage of a bone.
* Ewing's sarcoma: This is a malignant tumor that usually occurs in the long bones of the arms and legs.
* Multiple myeloma: This is a type of cancer that affects the plasma cells in the bone marrow.

Symptoms of bone neoplasms can include pain, swelling, or deformity of the affected bone, as well as weakness or fatigue. Treatment options depend on the type and location of the tumor, as well as the severity of the symptoms. Treatment may involve surgery, radiation therapy, chemotherapy, or a combination of these.

The causes of colorectal neoplasms are not fully understood, but factors such as age, genetics, diet, and lifestyle have been implicated. Symptoms of colorectal cancer can include changes in bowel habits, blood in the stool, abdominal pain, and weight loss. Screening for colorectal cancer is recommended for adults over the age of 50, as it can help detect early-stage tumors and improve survival rates.

There are several subtypes of colorectal neoplasms, including adenomas (which are precancerous polyps), carcinomas (which are malignant tumors), and lymphomas (which are cancers of the immune system). Treatment options for colorectal cancer depend on the stage and location of the tumor, but may include surgery, chemotherapy, radiation therapy, or a combination of these.

Research into the causes and treatment of colorectal neoplasms is ongoing, and there has been significant progress in recent years. Advances in screening and treatment have improved survival rates for patients with colorectal cancer, and there is hope that continued research will lead to even more effective treatments in the future.

There are different types of amnesia, including:

1. Retrograde amnesia: loss of memory of events that occurred before the onset of amnesia.
2. Anterograde amnesia: inability to form new memories after the onset of amnesia.
3. Transient global amnesia: temporary and reversible loss of memory due to a specific cause, such as a stroke or a head injury.
4. Korsakoff's syndrome: a condition caused by alcoholism and malnutrition that affects the hippocampus and the ability to form new memories.
5. Dissociative amnesia: loss of memory due to psychological trauma or stress, often accompanied by dissociation from reality.

The symptoms of amnesia can vary depending on the underlying cause and the severity of the condition. Some common symptoms include:

1. Difficulty learning new information
2. Forgetting recent events or conversations
3. Inability to recall past events or experiences
4. Confusion and disorientation
5. Difficulty with problem-solving and decision-making

The diagnosis of amnesia is based on a combination of medical history, physical examination, and neuropsychological tests. Imaging studies such as CT or MRI scans may also be used to rule out other causes of memory loss.

Treatment for amnesia depends on the underlying cause and may include:

1. Medications to manage symptoms such as anxiety, depression, or cognitive impairment.
2. Cognitive rehabilitation therapy to improve memory and problem-solving skills.
3. Behavioral interventions to help the individual adapt to their condition.
4. In some cases, surgery may be necessary to treat the underlying cause of amnesia, such as a tumor or a blood clot.

Overall, amnesia can have a significant impact on an individual's quality of life, but with proper diagnosis and treatment, many people are able to manage their symptoms and lead fulfilling lives.

Brain neoplasms can arise from various types of cells in the brain, including glial cells (such as astrocytes and oligodendrocytes), neurons, and vascular tissues. The symptoms of brain neoplasms vary depending on their size, location, and type, but may include headaches, seizures, weakness or numbness in the limbs, and changes in personality or cognitive function.

There are several different types of brain neoplasms, including:

1. Meningiomas: These are benign tumors that arise from the meninges, the thin layers of tissue that cover the brain and spinal cord.
2. Gliomas: These are malignant tumors that arise from glial cells in the brain. The most common type of glioma is a glioblastoma, which is aggressive and hard to treat.
3. Pineal parenchymal tumors: These are rare tumors that arise in the pineal gland, a small endocrine gland in the brain.
4. Craniopharyngiomas: These are benign tumors that arise from the epithelial cells of the pituitary gland and the hypothalamus.
5. Medulloblastomas: These are malignant tumors that arise in the cerebellum, specifically in the medulla oblongata. They are most common in children.
6. Acoustic neurinomas: These are benign tumors that arise on the nerve that connects the inner ear to the brain.
7. Oligodendrogliomas: These are malignant tumors that arise from oligodendrocytes, the cells that produce the fatty substance called myelin that insulates nerve fibers.
8. Lymphomas: These are cancers of the immune system that can arise in the brain and spinal cord. The most common type of lymphoma in the CNS is primary central nervous system (CNS) lymphoma, which is usually a type of B-cell non-Hodgkin lymphoma.
9. Metastatic tumors: These are tumors that have spread to the brain from another part of the body. The most common types of metastatic tumors in the CNS are breast cancer, lung cancer, and melanoma.

These are just a few examples of the many types of brain and spinal cord tumors that can occur. Each type of tumor has its own unique characteristics, such as its location, size, growth rate, and biological behavior. These factors can help doctors determine the best course of treatment for each patient.

Examples of neoplasms, germ cell and embryonal include:

1. Testicular cancer: This type of cancer develops in the cells of the testes and is most common in young men between the ages of 20 and 35.
2. Ovarian cancer: This type of cancer develops in the cells of the ovaries and is most common in older women.
3. Embryonal carcinoma: This type of cancer develops in the cells that form the embryo during fetal development. It is rare and tends to affect children and young adults.
4. Teratocarcinoma: This type of cancer develops in the cells that form the placenta during pregnancy. It is rare and tends to affect women who have abnormal pregnancies.

Neoplasms, germ cell and embryonal are typically treated with surgery, chemotherapy, or radiation therapy, depending on the location and severity of the cancer. The prognosis for these types of cancers is generally good if they are detected early and treated appropriately. However, if they are not diagnosed and treated promptly, they can spread to other parts of the body and be more difficult to treat.

There are several types of osteosarcomas, including:

1. High-grade osteosarcoma: This is the most common type of osteosarcoma and tends to grow quickly.
2. Low-grade osteosarcoma: This type of osteosarcoma grows more slowly than high-grade osteosarcoma.
3. Chondrosarcoma: This is a type of osteosarcoma that arises in the cartilage cells of the bone.
4. Ewing's family of tumors: These are rare types of osteosarcoma that can occur in any bone of the body.

The exact cause of osteosarcoma is not known, but certain risk factors may increase the likelihood of developing the disease. These include:

1. Previous radiation exposure
2. Paget's disease of bone
3. Li-Fraumeni syndrome (a genetic disorder that increases the risk of certain types of cancer)
4. Familial retinoblastoma (a rare inherited condition)
5. Exposure to certain chemicals, such as herbicides and industrial chemicals.

Symptoms of osteosarcoma may include:

1. Pain in the affected bone, which may be worse at night or with activity
2. Swelling and redness around the affected area
3. Limited mobility or stiffness in the affected limb
4. A visible lump or mass on the affected bone
5. Fractures or breaks in the affected bone

If osteosarcoma is suspected, a doctor may perform several tests to confirm the diagnosis and determine the extent of the disease. These may include:

1. Imaging studies, such as X-rays, CT scans, or MRI scans
2. Biopsy, in which a sample of tissue is removed from the affected bone and examined under a microscope for cancer cells
3. Blood tests to check for elevated levels of certain enzymes that are produced by osteosarcoma cells
4. Bone scans to look for areas of increased activity or metabolism in the bones.

White blood cells are an important part of the immune system, and they help to fight off infections and diseases. A low number of white blood cells can make a person more susceptible to infections and other health problems.

There are several different types of leukopenia, including:

* Severe congenital neutropenia: This is a rare genetic disorder that causes a severe decrease in the number of neutrophils, a type of white blood cell.
* Chronic granulomatous disease: This is a genetic disorder that affects the production of white blood cells and can cause recurring infections.
* Autoimmune disorders: These are conditions where the immune system mistakenly attacks its own cells, including white blood cells. Examples include lupus and rheumatoid arthritis.
* Bone marrow failure: This is a condition where the bone marrow does not produce enough white blood cells, red blood cells, or platelets.

Symptoms of leukopenia can include recurring infections, fever, fatigue, and weight loss. Treatment depends on the underlying cause of the condition and may include antibiotics, immunoglobulin replacement therapy, or bone marrow transplantation.

There are several types of lymphoma, including:

1. Hodgkin lymphoma: This is a type of lymphoma that originates in the white blood cells called Reed-Sternberg cells. It is characterized by the presence of giant cells with multiple nucleoli.
2. Non-Hodgkin lymphoma (NHL): This is a type of lymphoma that does not meet the criteria for Hodgkin lymphoma. There are many subtypes of NHL, each with its own unique characteristics and behaviors.
3. Cutaneous lymphoma: This type of lymphoma affects the skin and can take several forms, including cutaneous B-cell lymphoma and cutaneous T-cell lymphoma.
4. Primary central nervous system (CNS) lymphoma: This is a rare type of lymphoma that develops in the brain or spinal cord.
5. Post-transplantation lymphoproliferative disorder (PTLD): This is a type of lymphoma that develops in people who have undergone an organ transplant, often as a result of immunosuppressive therapy.

The symptoms of lymphoma can vary depending on the type and location of the cancer. Some common symptoms include:

* Swollen lymph nodes
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching

Lymphoma is diagnosed through a combination of physical examination, imaging tests (such as CT scans or PET scans), and biopsies. Treatment options for lymphoma depend on the type and stage of the cancer, and may include chemotherapy, radiation therapy, immunotherapy, or stem cell transplantation.

Overall, lymphoma is a complex and diverse group of cancers that can affect people of all ages and backgrounds. While it can be challenging to diagnose and treat, advances in medical technology and research have improved the outlook for many patients with lymphoma.

Some common types of memory disorders include:

1. Amnesia: A condition where an individual experiences memory loss, either partial or total, due to brain damage or other causes.
2. Dementia: A broad term that describes a decline in cognitive function, including memory loss, confusion, and difficulty with communication and daily activities. Alzheimer's disease is the most common cause of dementia.
3. Mild Cognitive Impairment (MCI): A condition characterized by memory loss and other cognitive symptoms that are more severe than normal age-related changes but not as severe as dementia.
4. Attention Deficit Hyperactivity Disorder (ADHD): A neurodevelopmental disorder that affects attention, impulse control, and hyperactivity. Memory problems are often a component of ADHD.
5. Traumatic Brain Injury (TBI): A condition that occurs when the brain is injured due to a blow or jolt to the head, which can result in memory loss and other cognitive problems.
6. Stroke: A condition where blood flow to the brain is interrupted, leading to brain cell death and potential memory loss.
7. Meningitis: An inflammatory condition that affects the membranes covering the brain and spinal cord, which can lead to memory loss and other cognitive problems.
8. Encephalitis: An inflammatory condition that affects the brain directly, leading to memory loss and other cognitive problems.
9. Chronic Fatigue Syndrome (CFS): A condition characterized by persistent fatigue, memory loss, and other cognitive symptoms.
10. Sleep Disorders: Sleep disturbances can affect memory and cognitive function, including conditions such as insomnia, sleep apnea, and restless leg syndrome.

The diagnosis of memory disorders typically involves a combination of medical history, physical examination, laboratory tests, and neuropsychological evaluations. The specific treatment approach will depend on the underlying cause of the memory loss, but may include medication, behavioral interventions, and lifestyle changes.

Disease progression can be classified into several types based on the pattern of worsening:

1. Chronic progressive disease: In this type, the disease worsens steadily over time, with a gradual increase in symptoms and decline in function. Examples include rheumatoid arthritis, osteoarthritis, and Parkinson's disease.
2. Acute progressive disease: This type of disease worsens rapidly over a short period, often followed by periods of stability. Examples include sepsis, acute myocardial infarction (heart attack), and stroke.
3. Cyclical disease: In this type, the disease follows a cycle of worsening and improvement, with periodic exacerbations and remissions. Examples include multiple sclerosis, lupus, and rheumatoid arthritis.
4. Recurrent disease: This type is characterized by episodes of worsening followed by periods of recovery. Examples include migraine headaches, asthma, and appendicitis.
5. Catastrophic disease: In this type, the disease progresses rapidly and unpredictably, with a poor prognosis. Examples include cancer, AIDS, and organ failure.

Disease progression can be influenced by various factors, including:

1. Genetics: Some diseases are inherited and may have a predetermined course of progression.
2. Lifestyle: Factors such as smoking, lack of exercise, and poor diet can contribute to disease progression.
3. Environmental factors: Exposure to toxins, allergens, and other environmental stressors can influence disease progression.
4. Medical treatment: The effectiveness of medical treatment can impact disease progression, either by slowing or halting the disease process or by causing unintended side effects.
5. Co-morbidities: The presence of multiple diseases or conditions can interact and affect each other's progression.

Understanding the type and factors influencing disease progression is essential for developing effective treatment plans and improving patient outcomes.

Liver neoplasms, also known as liver tumors or hepatic tumors, are abnormal growths of tissue in the liver. These growths can be benign (non-cancerous) or malignant (cancerous). Malignant liver tumors can be primary, meaning they originate in the liver, or metastatic, meaning they spread to the liver from another part of the body.

There are several types of liver neoplasms, including:

1. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer and arises from the main cells of the liver (hepatocytes). HCC is often associated with cirrhosis and can be caused by viral hepatitis or alcohol abuse.
2. Cholangiocarcinoma: This type of cancer arises from the cells lining the bile ducts within the liver (cholangiocytes). Cholangiocarcinoma is rare and often diagnosed at an advanced stage.
3. Hemangiosarcoma: This is a rare type of cancer that originates in the blood vessels of the liver. It is most commonly seen in dogs but can also occur in humans.
4. Fibromas: These are benign tumors that arise from the connective tissue of the liver (fibrocytes). Fibromas are usually small and do not spread to other parts of the body.
5. Adenomas: These are benign tumors that arise from the glandular cells of the liver (hepatocytes). Adenomas are usually small and do not spread to other parts of the body.

The symptoms of liver neoplasms vary depending on their size, location, and whether they are benign or malignant. Common symptoms include abdominal pain, fatigue, weight loss, and jaundice (yellowing of the skin and eyes). Diagnosis is typically made through a combination of imaging tests such as CT scans, MRI scans, and ultrasound, and a biopsy to confirm the presence of cancer cells.

Treatment options for liver neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Surgery may be an option for some patients with small, localized tumors, while others may require chemotherapy or radiation therapy to shrink the tumor before surgery can be performed. In some cases, liver transplantation may be necessary.

Prognosis for liver neoplasms varies depending on the type and stage of the cancer. In general, early detection and treatment improve the prognosis, while advanced-stage disease is associated with a poorer prognosis.

Peritoneal neoplasms are relatively rare, but they can be aggressive and difficult to treat. The most common types of peritoneal neoplasms include:

1. Peritoneal mesothelioma: This is the most common type of peritoneal neoplasm and arises from the mesothelial cells that line the abdominal cavity. It is often associated with asbestos exposure.
2. Ovarian cancer: This type of cancer originates in the ovaries and can spread to the peritoneum.
3. Appendiceal cancer: This type of cancer arises in the appendix and can spread to the peritoneum.
4. Pseudomyxoma peritonei: This is a rare type of cancer that originates in the abdominal cavity and resembles a mucin-secreting tumor.
5. Primary peritoneal cancer: This type of cancer originates in the peritoneum itself and can be of various types, including adenocarcinoma, squamous cell carcinoma, and sarcoma.

The symptoms of peritoneal neoplasms vary depending on the location and size of the tumor, but may include abdominal pain, distension, and difficulty eating or passing stool. Treatment options for peritoneal neoplasms depend on the type and stage of the cancer, but may include surgery, chemotherapy, and radiation therapy. Prognosis for peritoneal neoplasms is generally poor, with a five-year survival rate of around 20-30%.

There are several subtypes of carcinoma, including:

1. Adenocarcinoma: This type of carcinoma originates in glandular cells, which produce fluids or mucus. Examples include breast cancer, prostate cancer, and colon cancer.
2. Squamous cell carcinoma: This type of carcinoma originates in squamous cells, which are found on the surface layers of skin and mucous membranes. Examples include head and neck cancers, cervical cancer, and anal cancer.
3. Basal cell carcinoma: This type of carcinoma originates in the deepest layer of skin, called the basal layer. It is the most common type of skin cancer and tends to grow slowly.
4. Neuroendocrine carcinoma: This type of carcinoma originates in cells that produce hormones and neurotransmitters. Examples include lung cancer, pancreatic cancer, and thyroid cancer.
5. Small cell carcinoma: This type of carcinoma is a highly aggressive form of lung cancer that spreads quickly to other parts of the body.

The signs and symptoms of carcinoma depend on the location and stage of the cancer. Some common symptoms include:

* A lump or mass
* Pain
* Skin changes, such as a new mole or a change in the color or texture of the skin
* Changes in bowel or bladder habits
* Abnormal bleeding

The diagnosis of carcinoma typically involves a combination of imaging tests, such as X-rays, CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a small sample of tissue for examination under a microscope. Treatment options for carcinoma depend on the location and stage of the cancer and may include surgery, radiation therapy, chemotherapy, or a combination of these.

In conclusion, carcinoma is a type of cancer that originates in epithelial cells and can occur in various parts of the body. Early detection and treatment are important for improving outcomes.

References:

1. American Cancer Society. (2022). Carcinoma. Retrieved from
2. Mayo Clinic. (2022). Carcinoma. Retrieved from
3. MedlinePlus. (2022). Carcinoma. Retrieved from

Lymphatic metastasis occurs when cancer cells enter the lymphatic vessels and are carried through the lymphatic system to other parts of the body. This can happen through several mechanisms, including:

1. Direct invasion: Cancer cells can invade the nearby lymphatic vessels and spread through them.
2. Lymphatic vessel embolization: Cancer cells can block the flow of lymphatic fluid and cause the formation of a clot-like structure, which can trap cancer cells and allow them to grow.
3. Lymphatic vessel invasion: Cancer cells can infiltrate the walls of lymphatic vessels and spread through them.

Lymphatic metastasis is a common mechanism for the spread of cancer, particularly in the breast, melanoma, and other cancers that have a high risk of lymphatic invasion. The presence of lymphatic metastasis in a patient's body can indicate a more aggressive cancer and a poorer prognosis.

Treatment for lymphatic metastasis typically involves a combination of surgery, chemotherapy, and radiation therapy. Surgery may be used to remove any affected lymph nodes or other tumors that have spread through the lymphatic system. Chemotherapy may be used to kill any remaining cancer cells, while radiation therapy may be used to shrink the tumors and relieve symptoms.

In summary, lymphatic metastasis is a common mechanism for the spread of cancer through the body, particularly in cancers that originate in organs with a high lymphatic drainage. Treatment typically involves a combination of surgery, chemotherapy, and radiation therapy to remove or shrink the tumors and relieve symptoms.

There are several types of stomach neoplasms, including:

1. Adenocarcinoma: This is the most common type of stomach cancer, accounting for approximately 90% of all cases. It begins in the glandular cells that line the stomach and can spread to other parts of the body.
2. Squamous cell carcinoma: This type of cancer begins in the squamous cells that cover the outer layer of the stomach. It is less common than adenocarcinoma but more likely to be found in the upper part of the stomach.
3. Gastric mixed adenocarcinomasquamous cell carcinoma: This type of cancer is a combination of adenocarcinoma and squamous cell carcinoma.
4. Lymphoma: This is a cancer of the immune system that can occur in the stomach. It is less common than other types of stomach cancer but can be more aggressive.
5. Carcinomas of the stomach: These are malignant tumors that arise from the epithelial cells lining the stomach. They can be subdivided into adenocarcinoma, squamous cell carcinoma, and others.
6. Gastric brunner's gland adenoma: This is a rare type of benign tumor that arises from the Brunner's glands in the stomach.
7. Gastric polyps: These are growths that occur on the lining of the stomach and can be either benign or malignant.

The symptoms of stomach neoplasms vary depending on the location, size, and type of tumor. Common symptoms include abdominal pain, nausea, vomiting, weight loss, and difficulty swallowing. Diagnosis is usually made through a combination of endoscopy, imaging studies (such as CT or PET scans), and biopsy. Treatment depends on the type and stage of the tumor and may include surgery, chemotherapy, radiation therapy, or a combination of these. The prognosis for stomach neoplasms varies depending on the type and stage of the tumor, but early detection and treatment can improve outcomes.

Multiple myeloma is the second most common type of hematologic cancer after non-Hodgkin's lymphoma, accounting for approximately 1% of all cancer deaths worldwide. It is more common in older adults, with most patients being diagnosed over the age of 65.

The exact cause of multiple myeloma is not known, but it is believed to be linked to genetic mutations that occur in the plasma cells. There are several risk factors that have been associated with an increased risk of developing multiple myeloma, including:

1. Family history: Having a family history of multiple myeloma or other plasma cell disorders increases the risk of developing the disease.
2. Age: The risk of developing multiple myeloma increases with age, with most patients being diagnosed over the age of 65.
3. Race: African Americans are at higher risk of developing multiple myeloma than other races.
4. Obesity: Being overweight or obese may increase the risk of developing multiple myeloma.
5. Exposure to certain chemicals: Exposure to certain chemicals such as pesticides, solvents, and heavy metals has been linked to an increased risk of developing multiple myeloma.

The symptoms of multiple myeloma can vary depending on the severity of the disease and the organs affected. Common symptoms include:

1. Bone pain: Pain in the bones, particularly in the spine, ribs, or long bones, is a common symptom of multiple myeloma.
2. Fatigue: Feeling tired or weak is another common symptom of the disease.
3. Infections: Patients with multiple myeloma may be more susceptible to infections due to the impaired functioning of their immune system.
4. Bone fractures: Weakened bones can lead to an increased risk of fractures, particularly in the spine, hips, or ribs.
5. Kidney problems: Multiple myeloma can cause damage to the kidneys, leading to problems such as kidney failure or proteinuria (excess protein in the urine).
6. Anemia: A low red blood cell count can cause anemia, which can lead to fatigue, weakness, and shortness of breath.
7. Increased calcium levels: High levels of calcium in the blood can cause symptoms such as nausea, vomiting, constipation, and confusion.
8. Neurological problems: Multiple myeloma can cause neurological problems such as headaches, numbness or tingling in the arms and legs, and difficulty with coordination and balance.

The diagnosis of multiple myeloma typically involves a combination of physical examination, medical history, and laboratory tests. These may include:

1. Complete blood count (CBC): A CBC can help identify abnormalities in the numbers and characteristics of different types of blood cells, including red blood cells, white blood cells, and platelets.
2. Serum protein electrophoresis (SPEP): This test measures the levels of different proteins in the blood, including immunoglobulins (antibodies) and abnormal proteins produced by myeloma cells.
3. Urine protein electrophoresis (UPEP): This test measures the levels of different proteins in the urine.
4. Immunofixation: This test is used to identify the type of antibody produced by myeloma cells and to rule out other conditions that may cause similar symptoms.
5. Bone marrow biopsy: A bone marrow biopsy involves removing a sample of tissue from the bone marrow for examination under a microscope. This can help confirm the diagnosis of multiple myeloma and determine the extent of the disease.
6. Imaging tests: Imaging tests such as X-rays, CT scans, or MRI scans may be used to assess the extent of bone damage or other complications of multiple myeloma.
7. Genetic testing: Genetic testing may be used to identify specific genetic abnormalities that are associated with multiple myeloma and to monitor the response of the disease to treatment.

It's important to note that not all patients with MGUS or smoldering myeloma will develop multiple myeloma, and some patients with multiple myeloma may not have any symptoms at all. However, if you are experiencing any of the symptoms listed above or have a family history of multiple myeloma, it's important to talk to your doctor about your risk and any tests that may be appropriate for you.

There are several possible causes of thrombocytopenia, including:

1. Immune-mediated disorders such as idiopathic thrombocytopenic purpura (ITP) or systemic lupus erythematosus (SLE).
2. Bone marrow disorders such as aplastic anemia or leukemia.
3. Viral infections such as HIV or hepatitis C.
4. Medications such as chemotherapy or non-steroidal anti-inflammatory drugs (NSAIDs).
5. Vitamin deficiencies, especially vitamin B12 and folate.
6. Genetic disorders such as Bernard-Soulier syndrome.
7. Sepsis or other severe infections.
8. Disseminated intravascular coagulation (DIC), a condition where blood clots form throughout the body.
9. Postpartum thrombocytopenia, which can occur in some women after childbirth.

Symptoms of thrombocytopenia may include easy bruising, petechiae (small red or purple spots on the skin), and prolonged bleeding from injuries or surgical sites. Treatment options depend on the underlying cause but may include platelet transfusions, steroids, immunosuppressive drugs, and in severe cases, surgery.

In summary, thrombocytopenia is a condition characterized by low platelet counts that can increase the risk of bleeding and bruising. It can be caused by various factors, and treatment options vary depending on the underlying cause.

Germinomas are rare and account for only about 1% to 3% of all germ cell tumors. They are more common in children and young adults, and the median age at diagnosis is around 10 to 20 years. These tumors tend to grow slowly and may not cause any symptoms in their early stages.

The signs and symptoms of germinoma can vary depending on the location and size of the tumor. In general, they may include:

* Abdominal pain or discomfort
* Swelling or lump in the abdomen
* Vaginal bleeding or discharge in females
* Painful urination or scrotal swelling in males
* Fatigue or fever

If a germinoma is suspected, imaging tests such as CT scans, MRI scans, or ultrasound may be ordered to confirm the diagnosis. A biopsy may also be performed to examine the tumor cells under a microscope.

Treatment for germinoma typically involves surgery to remove the tumor and any affected tissues. In some cases, chemotherapy or radiation therapy may be recommended to ensure that all cancerous cells are eliminated. The prognosis for germinoma is generally good, with a five-year survival rate of around 90% for children and young adults. However, the tumor can recur in some cases, so follow-up care is important.

In summary, germinoma is a rare type of tumor that originates from germ cells in the reproductive system. It can be benign or malignant and tends to grow slowly, causing abdominal pain, swelling, or other symptoms. Treatment typically involves surgery and may include chemotherapy or radiation therapy, with a good prognosis for most patients.

The effects of sleep deprivation can be severe and long-lasting, including:

1. Impaired cognitive function: Sleep deprivation can affect attention, memory, and decision-making skills, making it more difficult to perform daily tasks and make sound judgments.
2. Emotional distress: Lack of sleep can lead to irritability, anxiety, and depression, which can negatively impact relationships and overall well-being.
3. Physical health problems: Chronic sleep deprivation has been linked to an increased risk of obesity, diabetes, cardiovascular disease, and immune system dysfunction.
4. Impaired motor function: Sleep deprivation can cause coordination problems, clumsiness, and a higher risk of accidents, particularly in activities that require attention and quick reflexes (e.g., driving).
5. Premature aging: Chronic sleep deprivation can accelerate the aging process and reduce the body's ability to repair and regenerate cells.
6. Reduced productivity and performance: Sleep deprivation can lead to decreased productivity, poor work quality, and increased absenteeism, which can negatively impact career advancement and financial stability.
7. Increased risk of accidents and injuries: Drowsy driving and workplace accidents are common consequences of sleep deprivation, which can result in fatalities and long-term disabilities.
8. Weakened immune system: Sleep deprivation can weaken the immune system, making it more difficult to fight off infections and diseases.
9. Negative impact on relationships: Sleep deprivation can lead to mood swings, irritability, and difficulty interacting with others, which can strain personal and professional relationships.
10. Increased risk of mental health disorders: Chronic sleep deprivation has been linked to an increased risk of developing anxiety, depression, and other mental health disorders.

To avoid these negative consequences, it's essential to prioritize sleep and make it a critical component of your daily routine. Establishing a consistent sleep schedule, creating a sleep-conducive environment, and practicing relaxation techniques can help improve sleep quality and duration. Additionally, avoiding stimulating activities before bedtime, limiting exposure to electronic screens, and seeking professional help if sleep problems persist can contribute to better overall health and well-being.

Benign CNS neoplasms include:

1. Meningiomas: These are the most common type of benign CNS tumor, arising from the meninges (the membranes covering the brain and spinal cord).
2. Acoustic neuromas: These tumors arise from the nerve cells that connect the inner ear to the brain.
3. Pineal gland tumors: These are rare tumors that occur in the pineal gland, a small gland located in the brain.
4. Craniopharyngiomas: These are rare tumors that arise from the remnants of the embryonic pituitary gland and can cause a variety of symptoms including headaches, vision loss, and hormonal imbalances.

Malignant CNS neoplasms include:

1. Gliomas: These are the most common type of malignant CNS tumor and arise from the supporting cells of the brain called glial cells. Examples of gliomas include astrocytomas, oligodendrogliomas, and medulloblastomas.
2. Lymphomas: These are cancers of the immune system that can occur in the CNS.
3. Melanomas: These are rare tumors that arise from the pigment-producing cells of the skin and can spread to other parts of the body, including the CNS.
4. Metastatic tumors: These are tumors that have spread to the CNS from other parts of the body, such as the breast, lung, or colon.

The diagnosis and treatment of central nervous system neoplasms depend on the type, size, location, and severity of the tumor, as well as the patient's overall health and medical history. Treatment options can include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy.

The prognosis for CNS neoplasms varies depending on the type of tumor and the effectiveness of treatment. In general, gliomas have a poorer prognosis than other types of CNS tumors, with five-year survival rates ranging from 30% to 60%. Lymphomas and melanomas have better prognoses, with five-year survival rates of up to 80%. Metastatic tumors have a more guarded prognosis, with five-year survival rates depending on the primary site of the cancer.

In summary, central nervous system neoplasms are abnormal growths of tissue in the brain and spinal cord that can cause a variety of symptoms and can be benign or malignant. The diagnosis and treatment of these tumors depend on the type, size, location, and severity of the tumor, as well as the patient's overall health and medical history. The prognosis for CNS neoplasms varies depending on the type of tumor and the effectiveness of treatment, but in general, gliomas have a poorer prognosis than other types of CNS tumors.

Mediastinal neoplasms are tumors or abnormal growths that occur in the mediastinum, which is the area between the lungs in the chest cavity. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Types of Mediastinal Neoplasms
------------------------------

There are several types of mediastinal neoplasms, including:

1. Thymoma: A tumor that originates in the thymus gland.
2. Thymic carcinoma: A malignant tumor that originates in the thymus gland.
3. Lymphoma: Cancer of the immune system that can occur in the mediastinum.
4. Germ cell tumors: Tumors that originate from germ cells, which are cells that form eggs or sperm.
5. Neuroendocrine tumors: Tumors that originate from cells of the nervous system and produce hormones.
6. Mesothelioma: A type of cancer that occurs in the lining of the chest cavity.
7. Metastatic tumors: Tumors that have spread to the mediastinum from another part of the body, such as the breast, lung, or colon.

Symptoms of Mediastinal Neoplasms
------------------------------

The symptoms of mediastinal neoplasms can vary depending on the type and location of the tumor. Some common symptoms include:

1. Chest pain or discomfort
2. Shortness of breath
3. Coughing
4. Fatigue
5. Weight loss
6. Swelling in the neck or face
7. Pain in the shoulders or arms
8. Coughing up blood
9. Hoarseness or difficulty swallowing

Diagnosis and Treatment of Mediastinal Neoplasms
-----------------------------------------------

The diagnosis of mediastinal neoplasms typically involves a combination of imaging tests such as chest X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. A biopsy may also be performed to confirm the diagnosis.

Treatment for mediastinal neoplasms depends on the type and location of the tumor, as well as the patient's overall health. Treatment options can include:

1. Surgery: Surgical removal of the tumor may be possible for some types of mediastinal neoplasms.
2. Radiation therapy: High-energy beams can be used to kill cancer cells.
3. Chemotherapy: Drugs can be used to kill cancer cells.
4. Targeted therapy: Drugs that target specific molecules involved in the growth and spread of cancer cells.
5. Immunotherapy: A type of treatment that uses the body's immune system to fight cancer.

Prognosis for Mediastinal Neoplasms
---------------------------------

The prognosis for mediastinal neoplasms depends on the type and location of the tumor, as well as the patient's overall health. In general, the prognosis is good for benign tumors, while the prognosis is guarded for malignant tumors. Factors that can affect the prognosis include:

1. Tumor size and location
2. Type of tumor
3. Extent of cancer spread
4. Patient's age and overall health
5. Response to treatment

Lifestyle Changes for Patients with Mediastinal Neoplasms
---------------------------------------------------

Patients with mediastinal neoplasms may need to make lifestyle changes to help manage their symptoms and improve their quality of life. These can include:

1. Eating a healthy diet
2. Getting regular exercise
3. Avoiding smoking and alcohol
4. Managing stress
5. Getting enough rest and sleep
6. Attending follow-up appointments with the doctor

Conclusion
----------

Mediastinal neoplasms are tumors that occur in the mediastinum, a region of the chest between the lungs. They can be benign or malignant, and their symptoms and treatment options vary depending on the type and location of the tumor. If you have been diagnosed with a mediastinal neoplasm, it is important to work closely with your healthcare team to determine the best course of treatment and manage any symptoms you may be experiencing. With appropriate treatment and lifestyle changes, many patients with mediastinal neoplasms can achieve long-term survival and a good quality of life.

SCC typically appears as a firm, flat, or raised bump on the skin, and may be pink, red, or scaly. The cancer cells are usually well-differentiated, meaning they resemble normal squamous cells, but they can grow rapidly and invade surrounding tissues if left untreated.

SCC is more common in fair-skinned individuals and those who spend a lot of time in the sun, as UV radiation can damage the skin cells and increase the risk of cancer. The cancer can also spread to other parts of the body, such as lymph nodes or organs, and can be life-threatening if not treated promptly and effectively.

Treatment for SCC usually involves surgery to remove the cancerous tissue, and may also include radiation therapy or chemotherapy to kill any remaining cancer cells. Early detection and treatment are important to improve outcomes for patients with SCC.

DLBCL is characterized by the rapid growth of malignant B cells in the lymph nodes, spleen, bone marrow, and other organs. These cells can also spread to other parts of the body through the bloodstream or lymphatic system. The disease is often aggressive and can progress quickly without treatment.

The symptoms of DLBCL vary depending on the location and extent of the disease, but they may include:

* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Night sweats
* Weight loss
* Abdominal pain or discomfort
* Itching

The diagnosis of DLBCL is based on a combination of physical examination findings, imaging studies (such as CT scans or PET scans), and biopsy results. Treatment typically involves a combination of chemotherapy, radiation therapy, and in some cases, immunotherapy or targeted therapy. The prognosis for DLBCL has improved significantly over the past few decades, with overall survival rates ranging from 60% to 80%, depending on the stage and other factors.

Retrograde amnesia can be caused by a variety of factors, including traumatic brain injury, stroke, infection, or degenerative diseases such as Alzheimer's disease. The exact cause of retrograde amnesia will depend on the underlying medical condition.

One well-known example of retrograde amnesia is the case of patient H.M., who underwent surgery to remove a severe epileptic focus in his brain in 1953. The surgery involved the removal of large portions of his medial temporal lobe, including the hippocampus and other structures critical for memory formation. As a result of the surgery, patient H.M. developed retrograde amnesia, unable to recall events that occurred before the surgery. However, he was able to form new memories after the surgery, leading researchers to study his case extensively and gain insights into the neural mechanisms of memory formation.

Retrograde amnesia can be diagnosed through a combination of medical history, physical examination, neuropsychological tests, and imaging studies such as CT or MRI scans. Treatment for retrograde amnesia will depend on the underlying cause, and may include medications, rehabilitation therapies, or other interventions aimed at improving memory function.

In summary, retrograde amnesia is a condition where an individual experiences memory loss for events that occurred before a specific point in time, usually as a result of brain injury or disease. The exact cause of retrograde amnesia will depend on the underlying medical condition, and diagnosis and treatment will be tailored to the individual case.

Source: National Cancer Institute (www.cancer.gov)

The above definition is given by the National Cancer Institute, which is an authoritative source of information on cancer and lymphoma. It provides a concise overview of follicular lymphoma, including its characteristics, diagnosis, treatment options, and prognosis. The definition includes key terms such as "slow-growing," "B cells," "lymph nodes," and "five-year survival rate," which are important to understand when discussing this type of cancer.

Sarcomas can arise in any part of the body, but they are most common in the arms and legs. They can also occur in the abdomen, chest, or head and neck. There are many different types of sarcoma, each with its own unique characteristics and treatment options.

The causes of sarcoma are not fully understood, but genetic mutations, exposure to radiation, and certain chemicals have been linked to an increased risk of developing the disease. Sarcomas can be challenging to diagnose and treat, as they often grow slowly and may not cause symptoms until they are advanced.

Treatment for sarcoma typically involves a combination of surgery, radiation therapy, and chemotherapy. The specific treatment plan will depend on the type of sarcoma, its location, and the stage of the disease. In some cases, amputation may be necessary to remove the tumor.

Prognosis for sarcoma varies depending on the type of cancer, the size and location of the tumor, and the stage of the disease. In general, the prognosis is best for patients with early-stage sarcoma that is confined to a small area and has not spread to other parts of the body.

Overall, sarcoma is a rare and complex form of cancer that requires specialized treatment and care. While the prognosis can vary depending on the specific type of cancer and the stage of the disease, advances in medical technology and treatment options have improved outcomes for many patients with sarcoma.

Some common types of head and neck neoplasms include:

1. Oral cavity cancer: Cancer that develops in the mouth, tongue, lips, or floor of the mouth.
2. Oropharyngeal cancer: Cancer that develops in the throat, including the base of the tongue, soft palate, and tonsils.
3. Hypopharyngeal cancer: Cancer that develops in the lower part of the throat, near the esophagus.
4. Laryngeal cancer: Cancer that develops in the voice box (larynx).
5. Paranasal sinus cancer: Cancer that develops in the air-filled cavities around the eyes and nose.
6. Salivary gland cancer: Cancer that develops in the salivary glands, which produce saliva to moisten food and keep the mouth lubricated.
7. Thyroid gland cancer: Cancer that develops in the butterfly-shaped gland in the neck that regulates metabolism and growth.

The risk factors for developing head and neck neoplasms include tobacco use, heavy alcohol consumption, human papillomavirus (HPV) infection, poor diet, and exposure to environmental carcinogens such as asbestos or radiation. Symptoms of head and neck neoplasms can vary depending on the location and size of the tumor, but may include a lump or swelling, pain, difficulty swallowing, bleeding, and changes in voice or breathing.

Diagnosis of head and neck neoplasms typically involves a combination of physical examination, imaging tests such as CT scans or MRI, and biopsy to confirm the presence of cancer cells. Treatment options can include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, depending on the type, location, and stage of the cancer.

Overall, head and neck neoplasms can have a significant impact on quality of life, and early detection and treatment are important for improving outcomes. If you suspect any changes in your head or neck, it is essential to consult with a healthcare professional for an accurate diagnosis and appropriate treatment.

Previous articleNeoplastic Cells
Next articleNephrocalcinosis

Examples of neoplasms, glandular and epithelial include:

* Adenomas: These are benign tumors that arise from glandular tissue. Examples include colon adenomas and prostate adenomas.
* Carcinomas: These are malignant tumors that arise from glandular or epithelial tissue. Examples include breast carcinoma, lung carcinoma, and ovarian carcinoma.
* Sarcomas: These are malignant tumors that arise from connective tissue. Examples include soft tissue sarcoma and bone sarcoma.

The diagnosis of neoplasms, glandular and epithelial is typically made through a combination of imaging tests such as X-rays, CT scans, MRI scans, and PET scans, along with a biopsy to confirm the presence of cancer cells. Treatment options for these types of neoplasms depend on the location, size, and stage of the tumor, but may include surgery, chemotherapy, radiation therapy, or a combination of these.

Overall, the term "neoplasms, glandular and epithelial" refers to a wide range of tumors that arise from glandular or epithelial tissue, and can be either benign or malignant. These types of neoplasms are common and can affect many different parts of the body.

Researchers also found some new chemotherapy method for specific cases. For example, The chemotherapy for ALL and gemtuzuab ... If the patients enter fully remission, the consolidation with stem cell transplantation is highly recommended. The prognosis ... Usually the chemotherapy is chosen according to the morphology of the blast (ALL or AML). A blood-forming stem-cell ... Recently, researches showed that using both myeloid and lymphoid induction therapy may be better for prognosis.Chemotherapy has ...
Chemotherapy drugs often used to treat AML are cytarabine and an anthracycline drug. Chemotherapy is broken down into 2 phases ... Consolidation therapy: second phase given in cycles that occur after the patient has recovered from induction therapy. Its ... Multiple chemotherapy drugs and its effects are being research in comparison to its treatment success in AML not specifically ... The aggressive chemotherapy regimen can lead to long-term side effects such as prolonged anemia, leukocytopenia, neutropenia, ...
Alternate chemotherapy is sometimes used at first relapse. For frontline treatment, CHOP with rituximab is the most common ... The phases of treatment are generally: frontline, following diagnosis, consolidation, after frontline response (to prolong ... A stronger chemotherapy with greater side effects (mostly hematologic) is HyperCVAD, often given in the hospital setting, with ... MCL cells may also be resistant to drug-induced apoptosis, making them harder to cure with chemotherapy or radiation. Cells ...
Often, they include combined induction chemotherapy and consolidation with high dose chemotherapy followed by autologous stem ... A standard treatment plan hasn't been established; common strategies involve chemotherapy and radiotherapy for individuals ...
First-line treatment of AML consists primarily of chemotherapy, and is divided into two phases: induction and consolidation. ... known as consolidation chemotherapy. This generally involves cytarabine, with the doses administered being higher in younger ... AML caused by previous chemotherapy) is expected to rise with an increase in the use of chemotherapy, an ageing population and ... This induction chemotherapy regimen is known as "7+3" (or "3+7"), because the cytarabine is given as a continuous IV infusion ...
59 Intensification chemotherapy is identical to consolidation chemotherapy but a different drug than the induction chemotherapy ... Consolidation chemotherapy is given after remission in order to prolong the overall disease-free time and improve overall ... Chemotherapy may be given with a curative intent or it may aim to prolong life or to palliate symptoms. Induction chemotherapy ... This type of chemotherapy is used for curative intent.: 55-59 Combined modality chemotherapy is the use of drugs with other ...
... acute myeloid leukemia is treated using chemotherapy consisting of an induction phase and consolidation phase (Dohner et al., ... adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of ...
Chemotherapy can be used alone or in combination with other therapies. Chemotherapy can be given either as a pill to swallow ... Consolidation/Intensification is used to kill any remaining cells that have the potential to become cancerous. It consists of ... "Chemotherapy to Treat Cancer". National Cancer Institute. 2015-04-29. Retrieved 2018-12-13. "High-dose Chemotherapy and Stem ... Consolidation begins after remission is obtained and is aimed at killing any remaining cancer cells. It will again vary ...
It is mostly used as consolidation therapy for relapsed or refractory lymphomas and relapsed or refractory Hodgkin disease, ... Sequential high-dose chemotherapy is a chemotherapy regimen consisting of several (2 to 4) sequential monochemotherapies with ... Chemotherapy regimens used in lymphoma, Chemotherapy regimens used in multiple myeloma). ... The idea behind this approach is that when using single-agent chemotherapy, the doctor can easily escalate the dose of the drug ...
Cancer (2015 PBS film) History of cancer History of cancer chemotherapy The Emperor of All Maladies: A Biography of Cancer " ... There were four phases: remission induction, remission consolidation or intensification, specific pre-emptive meningeal ... treatment and continuation chemotherapy for 3 years. Both radiotherapy and instillation of drug directly into spinal fluid were ...
In the 2000 European APL study, the 2-year relapse rate for those that did not receive consolidation chemotherapy (ATRA not ... based chemotherapy. Both chemotherapies result in a clinical remission in approximately 90% of patients with arsenic trioxide ... Unlike other chemotherapies, ATRA does not directly kill the malignant cells. ATRA induces the terminal differentiation of the ... ATRA alone is capable of inducing remission but it is short-lived in the absence of concurrent "traditional" chemotherapy. As ...
... followed by consolidation chemotherapy and autologous hematopoietic stem cell transplantation. Brentuximab vedotin is a ... Previous chemotherapy treatment regimens that did not use autologous stem cell transplantation reported poor prognoses with ... Optimal treatment of EATL has used regimens consisting of intensive chemotherapy, hematopoietic stem cell transplantation and, ... to repair obstructed or perforated bowel or remove bulky disease followed by a conditioning regimen of high-dose chemotherapy ( ...
Consolidation treatment often entails a repetition of induction chemotherapy or the intensification of chemotherapy with ... Such combination chemotherapy usually offers the benefits of early remission and a lower risk of disease resistance. ... Consolidation therapy or intensification therapy to eliminate any remaining leukemia cells. There are many different approaches ... Dental work is recommended before chemotherapy or radiation therapy. Those in remission can be treated per normal. The success ...
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with ... "7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as ... which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not ... always the case). The name "7+3" comes from the duration of chemotherapy course, which consists of 7 days of standard-dose ...
ADE is a chemotherapy regimen most often used as an induction or consolidation regimen in acute myelogenous leukemia, ... Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of ... regimen or who are relapsed after the standard chemotherapy. ADE regimen consists of three drugs: Ara-C (cytarabine) - an ... G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial (Chemotherapy regimens used in acute myeloid ...
... chemotherapy), a chemotherapy regimen Institute for Learning, a defunct UK body intended to promote teaching Indian Federation ... advocated consolidation of the British Empire Intact forest landscape Integrated Facility for Linux, an IBM mainframe processor ...
... and continue it during the consolidation/intensification period. Adult chemotherapy regimens mimic those of childhood ALL; ... In general, cytotoxic chemotherapy for ALL combines multiple antileukemic drugs tailored to each person. Chemotherapy for ALL ... Treatment usually also includes intrathecal chemotherapy since systemic chemotherapy can have limited penetration into the ... Chemotherapy is the initial treatment of choice, and most people with ALL receive a combination of medications. There are no ...
... as Consolidation After CAF in High-Risk Primary Breast Cancer Involving Ten or More Axillary Lymph Nodes (LN): Preliminary ... The high-dose chemotherapy resulted in a significantly low relapse rate, and high-dose chemotherapy was associated with ... High-dose chemotherapy and bone marrow transplant (HDC/BMT), also high-dose chemotherapy with autologous bone marrow transplant ... 2003). "Conventional Adjuvant Chemotherapy with or without High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in ...
Two other studies that included bortezomib in their chemotherapy regimens likewise found that the addition of autologous stem- ... drug regimen such as borezomib-lenalidomide-dexamethasone followed by autologous stem-cell transplantion and consolidation/ ... In one study, patients receiving intensive chemotherapy plus autologous stem-cell transplantation had a median survival of 34 ... months while those receiving chemotherapy alone had a median survival of 11 months. ...
... pulmonary consolidation, a mass, or a nodule". Pathologically, a cavity is "usually produced by the expulsion or drainage of a ... if a lung cancer develops cavitation after chemotherapy and radiofrequency ablation, that indicates a good response to ...
... and resistance to chemotherapy. In response, Prophylactic Intrathecal Chemotherapy is further enhanced with CNS radiation ... The treatment typically takes place over three stages: induction, consolidation, and maintenance. Treatment is expected to span ... Henceforth, Prophylactic Intrathecal Chemotherapy in CNS lymphoma, a treatment to lower risk of leukemia spreading to the ... Those who have had previous chemotherapy and exposure to radiation may have increased risks of developing T-ALL. CDKN2A is an ...
... two or more cycles of a platinum-based chemotherapy were randomly assigned to receive durvalumab or a placebo as consolidation ... Stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and ... demonstrated the efficacy of durvalumab in combination with platinum-based chemotherapy in the treatment of small cell lung ... Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination with Platinum-Based Chemotherapy ...
The goal of induction chemotherapy is to cure the cancer. It may be contrasted with neoadjuvant therapy, with consolidation ... "Chemotherapy for Acute Myeloid Leukemia (AML)". Vokes, E. E. (2010). "Induction Chemotherapy for Head and Neck Cancer: Recent ... and with maintenance chemotherapy given at lower doses after the consolidation phase of treatment is over. Induction ... Induction chemotherapy is the first-line treatment of cancer with a chemotherapeutic drug. ...
... as consolidation of the remission status obtained following surgery and standard platinum and taxane first line chemotherapy.[ ... May 2001). "Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune ... Nine hundred women in whom the ovarian tumour was removed by surgery and standard chemotherapy with paclitaxel and carboplatin ... In spite of initially successful treatment with surgery and chemotherapy, which forces back the tumour "completely", i.e. into ...
... chrysotherapy climatotherapy cobalt therapy cold compression therapy combination therapy consolidation therapy contrast bath ... brachytherapy cardiac resynchronization therapy cell therapy cytotherapy cell transfer therapy chelation therapy chemotherapy ...
... in combination with chemotherapy. The drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation ... high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients ... was found to prolong survival of FLT3-mutated AML patients when combined with conventional induction and consolidation ...
It is also used second-line for relapsed/refractory neuroblastoma in combination with chemotherapy and GM-CSF. Dinutuximab beta ... It is given in patients who have completed induction therapy and consolidation therapy (autologous bone marrow transplant and ... Dinutuximab is used as post-consolidation therapy for children with high-risk neuroblastoma, in combination with granulocyte- ...
Further studies on the usefulness of radiation, chemotherapy, bone marrow transplantation, and newer non-chemotherapy drugs ... for induction therapy and SMILE for consolidation therapy followed by autologous hemotopoietic stem cell transplantation. Two ... The disease can also occur in those who have had an organ transplantation or chemotherapy treatment or are presumed to have age ... In these cases, surgical removal appears to be the treatment of choice; the role of radiation and chemotherapy here is not well ...
Treatment with chemotherapy has been used with some success, particularly using lomustine, prednisone, doxorubicin, and ... sometimes leading to lung lobe consolidation and pleural effusion. Signs and symptoms include cough, loss of appetite, weight ...
Pneumonia can be described as pneumonitis combined with consolidation and exudation of lung tissue due to infection with ... Possible causative agents include radiation therapy of the chest, exposure to medications used during chemo-therapy, the ... and chemotherapy drugs "Farmer's lung" and "hot tub lung" are common names for types of hypersensitivity pneumonitis that ...
In 1999 Celltech led consolidation in the UK biosciences market merging with Chiroscience plc, after which it was briefly ... "Antibody-targeted chemotherapy with immunoconjugates of calicheamicin". Current Opinion in Pharmacology. 3 (4): 386-90. doi: ...
In mice lacking SHARP1/BHLHE41 and SHARP2, IGF-2 is elevated and leads to enhanced memory consolidation. There is a known amino ... Research is currently examining whether BHLHE40 and BHLHE41 can be used as target genes for chemotherapy. BHLHE41 is thought to ... Shahmoradi A, Radyushkin K, Rossner MJ (July 2015). "Enhanced memory consolidation in mice lacking the circadian modulators ...
"Murray Shear, chemotherapy pioneer passes away - The Washington Post Obituaries". The Washington Post. "Murray J. Shear Papers ... There followed the consolidation of the PHS facilities and the Harvard laboratory. They moved to the newly built NCI building ... Murray Shear was an American scientist who worked on cancer research and was a pioneer in the field of Chemotherapy. Murray ... He described the earliest accounts of cancer chemotherapy in a series of articles in the Journal of the National Cancer ...
Moran received a $447,000 debt consolidation loan at over 10% interest rate. The Lieutenant Governor of Virginia at the time, ... but after almost two years of chemotherapy and herbal therapies she was designated cancer free. His brother, Brian Moran, is a ...
... and each bronchiole the center of a small focus or nodule of pneumonic consolidation", and In the second Case "the areas ... British Journal of Pharmacology and Chemotherapy. 1 (4): 287-290. doi:10.1111/j.1476-5381.1946.tb00049.x. PMC 1509744. PMID ...
It is a condition where the alveoli are deflated down to little or no volume, as distinct from pulmonary consolidation, in ... If a tumor is blocking the airway, relieving the obstruction by surgery, radiation therapy, chemotherapy, or laser therapy may ...
The unification of the two hospitals was one of the most significant consolidations ever achieved by hospitals; it was in ... despite his own oncologist at Cedars-Sinai having recommended that he use the marijuana for his pain and chemotherapy. Dr. ...
Chemotherapy regimens used in acute myeloid leukemia, Chemotherapy regimens used in lymphoma). ... HDAC is also used as a consolidation regimen in acute myeloid leukemia after initial 7+3 induction. HDAC also can be used as ... R-HDAC, or R-HD-AraC ((R)ituximab plus (H)igh (D)ose (A)ra-(C)) is a chemotherapy regimen that is used, alternating with R-Maxi ...
The enterochromaffin cells not only react to bad food but are also very sensitive to irradiation and cancer chemotherapy. Drugs ... Gonzalez R, Chávez-Pascacio K, Meneses A (September 2013). "Role of 5-HT5A receptors in the consolidation of memory". ... They are particularly important in treating the nausea and vomiting that occur during anticancer chemotherapy using cytotoxic ... Cancer Chemotherapy and Pharmacology. 56 (3): 231-238. doi:10.1007/s00280-005-1033-0. PMID 15838653. S2CID 27576150. Frost M, ...
A systematic review from 2014 found that low doses of amphetamine also improve memory consolidation, in turn leading to ... British Journal of Pharmacology and Chemotherapy. 20: 278-284. doi:10.1111/j.1476-5381.1963.tb01467.x. PMC 1703637. PMID ... Amphetamine has been shown to improve consolidation of information (0.02 ≥ P ≤ 0.05), leading to improved recall. Devous MD, ...
These brain areas are implicated in memory retrieval and consolidation, language processing, and association of emotions. These ... April 2016). "Sex-specific effects of cytotoxic chemotherapy agents cyclophosphamide and mitomycin C on gene expression, ... and it has been demonstrated that older adults experience impairments in memory consolidation as their medial prefrontal ...
Combined chemotherapy and radiation enhances survival compared to chemotherapy followed by radiation, though the combination ... consolidation (pneumonia), or pleural effusion; however, some lung tumors are not visible by X-ray. Next, many undergo computed ... Limited stage SCLC is typically treated with a combination of chemotherapy and radiotherapy. For chemotherapy, the longstanding ... Chemotherapy has little effect in those with stage I NSCLC, and may worsen disease outcomes in those with the earliest disease ...
"No more chemotherapy for Cory, says close family friend". GMA News. July 2, 2009. Retrieved July 2, 2009. Agence France Presse ... Ban paid tribute to the former president for her "exceptional courage and pivotal role in the restoration and consolidation of ... Aquino pursued chemotherapy. Following the announcement, Malacañan Palace was saddened at the disclosure, while Senators ... It was announced that Aquino and her family had decided to discontinue the chemotherapy sessions and other medical intervention ...
The use of either radiotherapy or surgery in addition to an ALK inhibitor is known as local consolidation therapy, and as of ... It demonstrated a clear benefit against both first-line chemotherapy and first-line crizotinib. This was based on the phase 3 ... It provided good brain penetrance and a significant progression-free survival benefit against chemotherapy in the first line as ... March 2017). "First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer ( ...
The blockage of memory consolidation was proposed to be due to the inhibition by Ara-CTP of the DNA non-homologous end joining ... Cytarabine, also known as cytosine arabinoside (ara-C), is a chemotherapy medication used to treat acute myeloid leukemia (AML ... In mice, Ara-CTP (cytarabine-5'-triphosphate) blocks memory consolidation, but not short term memory, of a context fear ... October 2007). "Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid ...
Many hospitals merged and purchased physician practices, amounting to a significant consolidation of the provider industry. The ... as an increased likelihood that patients aged 19-25 with stage IIB-IIIC colorectal cancer receive timely adjuvant chemotherapy ...
... and side effects of acute myeloid leukemia chemotherapy, as well as the outlook. ... Consolidation. Doctors advise this phase of chemotherapy after a person has recovered from the induction phase. The aim of the ... Chemotherapy for AML involves three phases, according to the ACS. . These are the induction, consolidation, and maintenance ... This third phase involves receiving a low dose of a chemotherapy drug for months or years after the end of the consolidation ...
Treatment of patients with implants Consolidation therapy Treatment of recurrent disease General treatment approach Surgery is ... Chemotherapy recommendations for consolidation. Consolidation is treatment given after completion of front-line therapy with a ... Consider chemotherapy for stages 1A and 1B grades 2 and 3, and stage 1C. Chemotherapy is usually given after surgery. Regimens ... Neoadjuvant Chemotherapy. While neoadjuvant chemotherapy has been demonstrated as noninferior to primary cytoreductive surgery ...
Hence, ATRA-ATO in both chemotherapy-replacing and -reducing settings in consolidation is not inferior to ATRA-chemotherapy ( ... Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). ... Here, we evaluated whether chemotherapy could be replaced or reduced by ATO in APL patients at different risks. After achieving ... into ATO and non-ATO groups for consolidation ATRA-ATO versus ATRA-anthracycline for low-/intermediate-risk patients, or ATRA- ...
each cycle of chemotherapy for a maximum of 5 doses Adult patients with classical Hodgkin lymphoma consolidation 1.8 mg/kg up ... of 180 mg in combination with chemotherapy Administer every 3 weeks with each cycle of chemotherapy for 6 to 8 doses. ... Patients received ADCETRIS plus AVEPC chemotherapy at 1.8 mg/kg intravenously over 30 minutes prior to other chemotherapy in 21 ... In combination with chemotherapy Grade 2 Reduce dose to 0.9 mg/kg up to a maximum of 90 mg every 2 weeks ...
TAU, UCLA Researchers Develop Deep-Brain Stimulation in Sleep to Improve Memory Consolidation. ... Beyond weight gain, chemotherapy is also known to increase the risk of high blood pressure and glucose intolerance, a ... Moreover, the pre-chemotherapy composition of the intestinal microbiome can predict which patients will gain weight following ... "We have shown for the first time that the pre-treatment microbiome of patients that gained weight following chemotherapy is ...
Do not administer within the 24-hr period prior to chemotherapy. Induction or Consolidation Chemotherapy. Neupogen, Zarxio, ... Myelosuppressive, induction, or consolidation chemotherapy. *Obtain a CBC count and platelet count before instituting therapy ... following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia ... 5 mcg/kg SC/IV qDay initially; may increase by 5 mcg/kg for each chemotherapy cycle according to duration and severity of ANC ...
Consolidation Chemotherapy / methods* Actions. * Search in PubMed * Search in MeSH * Add to Search ... consolidation therapy with no consolidation. Methods: In this randomised, open-label, phase 3 study we recruited previously ... consolidation therapy with VRD significantly improved median progression-free survival compared with no consolidation (58·9 ... Intensification and consolidation therapy in multiple myeloma in the current era. Nadeem O, Ghobrial IM. Nadeem O, et al. ...
Consolidation Chemotherapy Actions. * Search in PubMed * Search in MeSH * Add to Search ... Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly ...
Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in ... Different CRT regimens with consolidation chemotherapy may lead to increased rates of complete tumor regression. The pur... ...
Second randomization: Patients are randomized to 1 of 4 consolidation treatment groups. Good risk patients are randomized to ... Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and ... Postinduction chemotherapy: Patients receive amsacrine IV over 1 hour, cytarabine IV continuously, and etoposide IV over 1 hour ... RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. ...
Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN® is indicated for reducing the ... Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy In a randomized, double-blind‚ placebo- ... following induction or consolidation chemotherapy treatment of adults with AML. ... No claim regarding the safety or efficacy of the chemotherapy regimens is made. The effects of NEUPOGEN® on tumor growth or on ...
Chemotherapy is the use of potent drugs or chemicals, often in combinations or intervals, to kill or damage cancer cells in the ... Post-remission, or consolidation, therapy. Induction Therapy. The first phase of AML and ALL chemotherapy is induction therapy ... Chemotherapy. Chemotherapy is the use of potent drugs or chemicals, often in combinations or intervals, to kill or damage ... Both new chemotherapy drugs and new ways to attack cancer cells continue to emerge as research progresses. Many chemotherapy ...
9. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first ... 4. Double intensive consolidation chemotherapy in adult acute myeloid leukemia.. Harousseau JL; Milpied N; Briere J; Desablens ... 2. [The current chemotherapy of acute myeloid leukemias in adults].. Poddubnaia IV; Perilov AA. Ter Arkh; 1993; 65(7):86-9. ... 1. Induction chemotherapy for acute myelogenous leukemia.. Kalaycio M. Curr Hematol Rep; 2005 Jan; 4(1):49-50. PubMed ID: ...
It is unclear whether STK11m affects prognosis of stage III NSCLC or predicts response to ICI consolidation after CCRT. In ... in patients with good performance status is treated with concurrent platinum based chemotherapy with definitive dose radiation ... and consolidation ICI 6/11 (55%) vs. 17/59 (29%). Regarding the 6 STK11m pts who received ICI (4 pembrolizumab, 2 durvalumab), ... advanced stage NSCLC, STK11m has been associated with poor response to chemotherapy and ICI, and inferior survival outcomes.[9- ...
Arsenic is currently used for induction and consolidation chemotherapy for acute promyelocytic leukemia and other cancers [ ...
Consolidation chemotherapy prevents relapse by indirectly regulating bone marrow adipogenesis in patients with acute myeloid ... and ultimately protect MM cells from chemotherapy-induced apoptosis (88). Resistin protects MM cells from chemotherapy-induced ... Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget (2015) 6: ... Growth differentiation factor 15, which is secreted by marrow mononuclear cells in response to chemotherapy and partially ...
In the second phase, which is often called the consolidation phase, they receive additional chemotherapy to sustain the ... The first, midostaurin (Rydapt), was approved by the FDA for use during the induction and consolidation phases of treatment for ... In the first phase, which is often called the induction phase, patients are treated with chemotherapy to induce remission. ... or who have chronic health conditions or diseases that prevent them being treated with the standard intensive chemotherapy. A ...
Prior treatment may include chemotherapy, chemotherapy/radiation therapy, and/or consolidation/maintenance therapy. -Prior ... Subject must have no more than 3 prior lines of therapy in the recurrent setting, including platinum-based chemotherapy for ... Prior neoadjuvant or adjuvant chemotherapy included in initial treatment are not considered first- or later-line treatment ...
... and AI consolidation [cytarabine (0.5 g/m2)/idarubicin] three months after the start of treatment. The patient presented ... HLH during chemotherapy frequently occurs in patients who have already achieved remission and could be a result of the immune ... The chemotherapy regimen was initiated, and she achieved complete remission six months later, relapsing after four months with ... In this paper, we described a case of HLH with blast phagocytosis in a child with relapsed AMoL after chemotherapy. ...
SEA/RC9/R19 - Mass Campaign Consolidation Team  World Health Organization. Regional Office for South-East Asia (‏1956-01-01‎, ... SEA/RC9/R12 - Domiciliary Chemotherapy Expansion  World Health Organization. Regional Office for South-East Asia (‏1956-01-01‎ ...
Chemotherapy-induced anemia in patients with non-myeloid malignancies. • Reduction of allogeneic red blood cell transfusion in ... Reduce time to neutrophil recovery and fever duration after induction/consolidation in AML ... Decrease incidence of infection (febrile neutropenia) in patients on myelosuppressive chemotherapy. pegfilgrastim-bmez. ... Decrease incidence of infection (febrile neutropenia) in patients on myelosuppressive chemotherapy. • ...
As many as 100% of patients with a positive PET scan after chemotherapy have an early relapse, while in more than 80% of ... Features indistinguishable from pneumonic change, such as bilateral airspace consolidation and segmental or lobar atelectasis, ... Ceriani L, Suriano S, Ruberto T, Zucca E, Giovanella L. 18F-FDG uptake changes in liver and mediastinum during chemotherapy in ... F18 FDG-PET uptake variability within the liver and mediastinum during chemotherapy should be taken into account when this ...
Consolidation Chemotherapy Preferred Term Term UI T787095. Date03/14/2011. LexicalTag NON. ThesaurusID NLM (2012). ... Consolidation Chemotherapy Preferred Concept UI. M0555608. Scope Note. Drug treatment designed to further diminish the disease ... It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY.. Terms. ... It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY.. Public MeSH ...
Among GGO, patchy consolidation is located along the bronchovascular bundle. (D) PCP in a cancer patient who was receiving ... chemotherapy and high-dose corticosteroid. Cysts are observed within the affected area, suggesting that they were formed by PCP ...
... induction or consolidation chemotherapy, or patients with major antibody deficiencies receiving immunoglobulins. Inactivated ... Patients on chemotherapy with anti-B cell antibodies (e.g., rituximab) should wait at least 6 months after therapy before being ... Persons receiving chemotherapy or radiation for leukemia and other hematopoietic malignancies, or for solid tumors, should be ... Children 12 through 59 months who are at high risk for invasive Hib disease (i.e., recipients of chemotherapy or radiation for ...
No prior non-cytotoxic chemotherapy for recurrent or persistent disease. - At least 1 week since prior hormonal therapy for the ... Initial therapy may have included high-dose therapy, consolidation, or extended. therapy administered after surgical or non- ... Must have received 1 prior chemotherapy regimen for endometrial carcinoma. - ...
... which show that adding blinatumomab to consolidation chemotherapy resulted in a significantly better overall survival in adult ... followed by consolidation. And the consolidation regimens have several options. So you can use whole brain radiation therapy or ... lymphoma and the factors associated with consolidation therapy selection, outcomes after consolidation therapy accounting for ... And when we looked at the pattern of consolidation regimens, we saw what we anticipated. We did see a decrease in the use of ...
Selinexor was dosed at 60 mg PO on days 1, 3, 8, 10, 15 and 17 during induction and consolidation and on days 1 and 8 every 21 ... 633 Frontline Selinexor and Chemotherapy Is Highly Active in Older Adults with Acute Myeloid Leukemia (AML) Program: Oral and ... This abstract reports the ongoing results of a randomized phase II study of induction and consolidation with or without ... Patients in the selinexor arm who completed all consolidation could then move to maintenance therapy with selinexor alone. ...
  • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). (nih.gov)
  • Different CRT regimens with consolidation chemotherapy may lead to increased rates of complete tumor regression. (biomedcentral.com)
  • For consolidation therapy to provide substantial improvement in CR duration, intensive regimens with non-cross-resistant drugs will be required. (nih.gov)
  • 14. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia. (nih.gov)
  • Primary CNS lymphoma is a disease that typically involves a treatment of high dose methotrexate containing regimens, followed by consolidation. (ascopost.com)
  • And the consolidation regimens have several options. (ascopost.com)
  • And so at Memorial Sloan Kettering, we wanted to look into some of the practice patterns and how they've changed, and then also understand really the comparison and outcomes between these different consolidation regimens. (ascopost.com)
  • We saw that there are 385 patients who went on to get consolidation regimens. (ascopost.com)
  • And when we looked at the pattern of consolidation regimens, we saw what we anticipated. (ascopost.com)
  • We saw that patient associated factors were contributors to which consolidation regimens were selected. (ascopost.com)
  • And interestingly, we account for all those patient factors and also the induction regimens that were used, we saw that there was no significant difference in progression-free and overall survival between the different consolidation groups. (ascopost.com)
  • So our main takeaway is one, these modern consolidation regimens like stem cell transplant and reduced dose whole brain radiation, actually have really encouraging outcomes in this disease. (ascopost.com)
  • The phase III PROCLAIM trial, recently published in the Journal of Clinical Oncology entitled "PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer", compared two different chemotherapy regimens given concurrently with radiotherapy in patients with stage III non-squamous lung cancer: pemetrexed plus cisplatin versus cisplatin plus etoposide [ 2 ]. (oncotarget.com)
  • The nature and duration of chemotherapy treatment will vary depending on the type of AML a person has, but most people who receive chemotherapy for AML do go into remission. (medicalnewstoday.com)
  • After achieving complete remission with ATRA-ATO-based induction therapy , patients were randomized (11) into ATO and non-ATO groups for consolidation ATRA-ATO versus ATRA- anthracycline for low-/intermediate- risk patients , or ATRA-ATO- anthracycline versus ATRA- anthracycline - cytarabine for high- risk patients . (bvsalud.org)
  • Compare 4 vs 5 courses of total treatment, with either chemotherapy or bone marrow transplantation (BMT) as the final course, with respect to remission duration, relapse rate, disease free mortality, and overall survival in these patients. (clinicaltrials.gov)
  • Compare allogeneic or autologous BMT vs conventional chemotherapy with respect to remission duration, relapse rate, disease free mortality, and overall survival in these patients. (clinicaltrials.gov)
  • The Eastern Cooperative Oncology Group conducted a randomized study to determine the efficacy of consolidation therapy in prolonging the duration of complete remission (CR) in adults with acute nonlymphocytic leukemia (ANLL). (nih.gov)
  • The goal of chemotherapy is to damage or kill cancer cells so there's either no sign of illness (remission) or the disease's progress is slowed. (schoolandyouth.org)
  • Chemotherapy can produce long-term remission or outright cure for many persons, depending on the cancer type and its extent. (schoolandyouth.org)
  • Clinical and cytogenetic remission by means of intensive chemotherapy]. (nih.gov)
  • 9. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. (nih.gov)
  • In the first phase, which is often called the induction phase, patients are treated with chemotherapy to induce remission. (aacr.org)
  • In the second phase, which is often called the consolidation phase, they receive additional chemotherapy to sustain the remission. (aacr.org)
  • The chemotherapy regimen was initiated, and she achieved complete remission six months later, relapsing after four months with a complex karyotype involving chromosomes 8p and 16q. (scielo.br)
  • Drug treatment designed to further diminish the disease toward complete remission following INDUCTION CHEMOTHERAPY . (nih.gov)
  • Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug midostaurin. (nih.gov)
  • If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with the experimental drug midostaurin. (nih.gov)
  • All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. (nih.gov)
  • Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and placebo. (nih.gov)
  • There are three parts to the study treatment: remission induction therapy, remission consolidation therapy and continuation therapy. (nih.gov)
  • Doctors recommend chemotherapy to treat acute myeloid leukemia (AML). (medicalnewstoday.com)
  • Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). (bvsalud.org)
  • 1. Induction chemotherapy for acute myelogenous leukemia. (nih.gov)
  • 2. [The current chemotherapy of acute myeloid leukemias in adults]. (nih.gov)
  • 4. Double intensive consolidation chemotherapy in adult acute myeloid leukemia. (nih.gov)
  • 12. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial. (nih.gov)
  • 15. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. (nih.gov)
  • Arsenic is currently used for induction and consolidation chemotherapy for acute promyelocytic leukemia and other cancers [Miller et al. (cdc.gov)
  • To describe the case of a child who presented hemophagocytic lymphohistiocytosis (HLH) associated with acute monocytic leukemia after chemotherapy, with hemophagocytosis caused by leukemic cells. (scielo.br)
  • This is an open-label Phase 1b/2 clinical study of Samalizumab given in addition to standard induction chemotherapy/consolidation, followed by Samalizumab maintenance, in newly diagnosed acute myeloid leukemia. (clinicaltrials.gov)
  • Sargramostim is a colony stimulating factor that is FDA approved for the treatment of granulocytopenia following induction chemotherapy in acute myelogenous leukemia , mobilization and following transplantation of autologous peripheral blood progentior cells, myeloid reconstitution after autologous bone marrow transplantation, myeloid reconstitution after allogeneic bone marrow transplantation and bone marrow transplantation failure or engraftment delay. (wikidoc.org)
  • Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. (nih.gov)
  • However, the trial also showed increased toxicity with IP chemotherapy versus IV chemotherapy. (medscape.com)
  • Consolidation therapy resulted in hematologic toxicity, but was not lethal in any of the eligible patients. (nih.gov)
  • The recommended dose is 250 mcg/m2/day administered IV over a 2-hour period beginning two to four hours after bone marrow infusion, and not less than 24 hours after the last dose of chemotherapy or radiotherapy. (wikidoc.org)
  • High-risk features such as stage IC, higher grade, or clear-cell histology should prompt consideration of adjuvant chemotherapy. (medscape.com)
  • A new study, just published in the journal BMC Medicine ( The intestinal microbiome, weight, and metabolic changes in women treated by adjuvant chemotherapy for breast and gynecological malignancies ), suggests that gut bacteria are partially responsible for metabolic changes that lead to weight gain following chemotherapy treatment. (jewishpress.com)
  • This third phase involves receiving a low dose of a chemotherapy drug for months or years after the end of the consolidation phase. (medicalnewstoday.com)
  • Very high dose chemotherapy followed by stem cell transplantation can also be used. (schoolandyouth.org)
  • Unresectable stage III non-small cell lung cancer (NSCLC) in patients with good performance status is treated with concurrent platinum based chemotherapy with definitive dose radiation (CCRT) followed by the PD-L1 inhibitor, durvalumab. (medscape.com)
  • According to the FDA, it was approved for use in combination with a low dose of the cytotoxic chemotherapeutic cytarabine after results from a phase II clinical trial showed that adding glasdegib to low-dose cytarabine almost doubled median overall survival for patients newly diagnosed with AML who could not have intensive chemotherapy due to age or comorbidities. (aacr.org)
  • D) PCP in a cancer patient who was receiving chemotherapy and high-dose corticosteroid. (koreamed.org)
  • Responding patients could go on to high dose cytarabine consolidation with or without selinexor as per initial randomization. (confex.com)
  • Consolidation consisted of cytarabine at 1.5 gm/m 2 given Q12 hours days 1-3 with G-CSF given 24 hours following the last dose of cytarabine. (confex.com)
  • Today's treatments for leukemia, lymphoma and myeloma sometimes combine chemotherapy with radiation therapy. (schoolandyouth.org)
  • So you can use whole brain radiation therapy or stem cell transplant or just chemotherapy alone. (ascopost.com)
  • Induction chemotherapy with daunorubicin, cytosine arabinoside, and 6-thioguanine (DAT) yielded CR in 65% of 283 patients with ANLL, aged 16-69. (nih.gov)
  • The purpose of this study is to compare the effects, good and/or bad, of a standard chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine combined with or without midostaurin (also known as PKC412), to find out which is better. (nih.gov)
  • Meanwhile, we saw an increased use of stem cell transplant and also cytarabine or chemotherapy alone. (ascopost.com)
  • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). (nih.gov)
  • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). (nih.gov)
  • The recommended dosage in combination with chemotherapy for adult patients with previously untreated Stage III or IV cHL is 1.2 mg/kg up to a maximum of 120 mg every 2 weeks for a maximum of 12 doses ( 2.1 ). (nih.gov)
  • The recommended dosage in combination with chemotherapy for adult patients with previously untreated PTCL is 1.8 mg/kg up to a maximum of 180 mg every 3 weeks for 6 to 8 doses ( 2.1 ). (nih.gov)
  • The significance of STK11 m in stage III NSCLC pts treated with concurrent chemoradiation (CCRT) with or without consolidation ICI is unknown. (medscape.com)
  • In addition, grade 3 to 4 hematological toxicities were significantly reduced in the ATO group during consolidation. (bvsalud.org)
  • According to the FDA, almost 50 percent of adults with AML, many of whom are older adults, are not treated with the standard intensive chemotherapy because of toxicities related to the treatment and comorbidities. (aacr.org)
  • Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. (clinicaltrials.gov)
  • On Nov. 21, 2018, the FDA approved both glasdegib (Daurismo) and venetoclax (Venclexta) for treating patients with newly diagnosed AML who are age 75 or older, or who have chronic health conditions or diseases that prevent them being treated with the standard intensive chemotherapy. (aacr.org)
  • This approval was based on results from two phase I/II clinical trials that enrolled patients newly diagnosed with AML who could not have intensive chemotherapy due to age or comorbidities. (aacr.org)
  • The consolidation phase may involve receiving high doses of a medication for 5 days. (medicalnewstoday.com)
  • These results suggest that approaches to consolidation therapy employing reduced doses of the induction therapy regimen can have, at best, only a small benefit. (nih.gov)
  • AML chemotherapy usually starts with 1 week of intense treatment. (medicalnewstoday.com)
  • According to the American Cancer Society (ACS) , chemotherapy is the main treatment option for people with AML. (medicalnewstoday.com)
  • Approximately 30% of breast cancer patients who receive chemotherapy treatment gain weight, though it is unclear why this phenomenon occurs in some women but not in others. (jewishpress.com)
  • These findings suggest that bacteria are partially responsible for metabolic changes that lead to weight gain following chemotherapy treatment. (jewishpress.com)
  • We have shown for the first time that the pre-treatment microbiome of patients that gained weight following chemotherapy is different than the microbiome of patients that did not gain weight and that fecal transplantation from patients that gained weight results in glucose intolerance, adverse lipid changes and inflammatory changes in germ-free mice," says Prof. Koren. (jewishpress.com)
  • Moreover, the pre-chemotherapy composition of the intestinal microbiome can predict which patients will gain weight following treatment. (jewishpress.com)
  • Dr. Shai and Prof. Koren are currently in the midst of a follow-up study that aims to examine the results in a larger patient population and to examine the microbiome of women at the end of chemotherapy in order to understand the effect of the treatment on bacterial composition. (jewishpress.com)
  • The progress in treatment and survival for patients with blood cancers is largely due to the development of chemotherapy drugs over the past 40 years. (schoolandyouth.org)
  • This research is being done because it is unknown whether the addition of midostaurin to chemotherapy treatment is better than chemotherapy treatment alone. (nih.gov)
  • In this study, patients will receive either the experimental agent (midostaurin) or placebo combined with chemotherapy treatment. (nih.gov)
  • In this review, we address the role of redox homeostasis in cancer growth and therapy and examine the current literature regarding the redox regulatory systems that become upregulated in cancer and their role in promoting tumor progression and resistance to chemotherapy. (hindawi.com)
  • Kathryn R. Tringale, MD , of Memorial Sloan Kettering Cancer Center, discusses an assessment of 559 patients with primary central nervous system (CNS) lymphoma and the factors associated with consolidation therapy selection, outcomes after consolidation therapy accounting for patient factors, and patterns of disease failure. (ascopost.com)
  • Although traditional chemotherapy is still the main method in certain cancers, it has exposed much more serious problems and limitations in daily clinical work. (oncotarget.com)
  • Because of the patient's risk status, the physicians intended to perform allogeneic stem cell transplantation after induction and consolidation chemotherapy, which was scheduled to end in January 2013, and a conditioning chemotherapy regimen, which was planned to be given in March. (cdc.gov)
  • Currently, Kashton is on a daily chemotherapy medication and attends monthly clinic visits every month. (acco.org)
  • Hence, ATRA-ATO in both chemotherapy -replacing and -reducing settings in consolidation is not inferior to ATRA- chemotherapy (https//www.clinicaltrials.gov/, NCT01987297). (bvsalud.org)
  • Patients receiving consolidation plus maintenance therapy experienced a longer CR duration (40 wk) and disease-free survival at 2 yr (28%) than did those patients receiving maintenance therapy alone (34 wk and 14%, respectively). (nih.gov)
  • So patients who did not have a complete response to induction therapy were more likely to get chemotherapy alone as opposed to stem cell transplant. (ascopost.com)
  • Patients in the selinexor arm who completed all consolidation could then move to maintenance therapy with selinexor alone. (confex.com)
  • Conclusions: Selinexor in combination with standard induction and consolidation therapy appears highly active in older patients with de novo AML. (confex.com)
  • With systemic chemotherapy, the bloodstream circulates the drugs throughout the body. (medicalnewstoday.com)
  • Although doctors may sometimes prescribe a single chemotherapy drug, they often recommend a combination of such drugs, according to the NCI . (medicalnewstoday.com)
  • RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. (clinicaltrials.gov)
  • Chemotherapy is the use of potent drugs or chemicals, often in combinations or intervals, to kill or damage cancer cells in the body. (schoolandyouth.org)
  • Chemotherapy drugs are often called anticancer agents. (schoolandyouth.org)
  • All chemotherapy drugs interfere with cancer cells' ability to grow or multiply. (schoolandyouth.org)
  • That's why it's essential that the disease be accurately diagnosed: Certain chemotherapy drugs are used only for certain disease cell types. (schoolandyouth.org)
  • Both new chemotherapy drugs and new ways to attack cancer cells continue to emerge as research progresses. (schoolandyouth.org)
  • Many chemotherapy drugs attack cancer cells by interacting with the cancer cell's DNA or RNA (genetic makeup). (schoolandyouth.org)
  • Temporary hair loss is a common side-effect of many chemotherapy drugs. (clarkperdue.com)
  • This article looks at the phases, duration, and side effects of chemotherapy for AML, as well as the outlook. (medicalnewstoday.com)
  • Doctors usually recommend a combination of chemotherapy medications rather than a single one. (medicalnewstoday.com)
  • This abstract reports the ongoing results of a randomized phase II study of induction and consolidation with or without selinexor in newly diagnosed patients with AML, 60 years of age or older and preclinical studies to assess the mechanisms of chemo-sensitization. (confex.com)
  • So there's been a shift towards stem cell transplant or even chemotherapy alone. (ascopost.com)
  • And then when we looked at the disease patterns of failure, we saw that patients who achieved a complete response to their initial consolidation when they failed later on down the line, we could not predict where they would fail. (ascopost.com)
  • The aim of the consolidation phase is to kill the small number of leukemia cells left behind. (medicalnewstoday.com)
  • However, successful chemotherapy depends on the fact that cancerous cells are more sensitive to the chemicals in the drug than normal cells are. (schoolandyouth.org)
  • The panel noted that nearly 90 cases, alleging permanent hair loss resulting for the use of the chemotherapy drug, Taxotere, have been filed throughout the country. (clarkperdue.com)
  • Taxotere is a chemotherapy drug most often prescribed to breast cancer patients. (clarkperdue.com)
  • Chemotherapy either kills cancer cells or stops them from dividing. (medicalnewstoday.com)
  • Because chemotherapy affects healthy cells as well as cancer cells, it may lead to side effects. (medicalnewstoday.com)
  • These are the induction, consolidation, and maintenance phases. (medicalnewstoday.com)
  • It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY . (nih.gov)
  • Selinexor was dosed at 60 mg PO on days 1, 3, 8, 10, 15 and 17 during induction and consolidation and on days 1 and 8 every 21 days during maintenance. (confex.com)
  • All patients with stage II or higher cancer should be considered for front-line chemotherapy based on burden of disease and ability to achieve optimal primary resection. (medscape.com)